MyDx (MYDX) 10-K/A 26 Apr 17 2016 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 23, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	MyDx, Inc.
Entity Central Index Key	1,582,341
Amendment Flag	true
Amendment Description	EXPLANATORY NOTE We are filing this Amendment No. 1 to our Annual Report on Form 10-K/A (the “Amendment”) for the fiscal year ended December 31, 2016, as filed with the Securities and Exchange Commission (the “SEC”) on April 20, 2017 (the “Original Form 10-K”), to make the following changes: (i) to correct a typographical error in the Net Cash Provided by Financing Activities paragraph in Part II, Item 7; (ii) to correct grammatical errors in the Report of Independent Registered Public Accounting Firm of BPM LLP for the year ended December 31, 2015; (iii) to make certain corrections to: (a) the audited Consolidated Statement of Cash Flows for the year ended December 31, 2015; and (b) Notes 5, 8, 10, and 11 to our audited financial statements; (iv) to correct a typographical error in Part II, Item 9; (v) to make certain corrections to Part III, Items 12 and 14; and (vi) to include, as Exhibits 23.1 and 23.2, consents from our Independent Registered Public Accounting Firms for the years ended December 31, 2016 (Anton & Chia, LLP) and December 31, 2015 (BPM LLP) to incorporate their reports with respect to the consolidated financial statements for those respective years for incorporation by reference into our Registration Statement (Form S-8 No. 333-215979). In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have included the entire text of Part II, Items 7, 8, and 9 and Part III, Items 12 and 14 of the Original Form 10-K in this Amendment. This Amendment includes new certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 as Exhibits 31.1, 31.2, 32.1, and 3 hereto. Except as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information in any other Item of the Original Form 10-K or reflect any events that have occurred after the filing of the Original Form 10-K.
Current Fiscal Year End Date	--12-31
Document Type	10-K/A
Trading Symbol	MYDX
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,738,196.74
Entity Common Stock, Shares Outstanding		1,450,204,599

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 38,203	$ 143,680
Accounts receivable	27,851	10,702
Inventory	155,233	451,973
Prepaid expenses and other current assets	79,965	51,978
Total current assets	301,252	658,333
Property and equipment, net	138,883	233,064
Other assets	49,845	104,365
Total assets	489,980	995,762
Current liabilities:
Asset based loans	120,460
Accounts payable	1,082,384	619,528
Customer deposits	16,767	9,467
Accrued liabilities	131,563	281,761
Current portion of leases payable	3,480	2,773
Due to related party	1,075	1,075
Convertible notes payable, current, net of debt discount	233,147	50,574
Derivative liability	1,812,441
Warrant liability	247,203
Total current liabilities	3,648,520	965,178
Convertible note payable - related party	200,000	175,000
Convertible notes payable		200,274
Other long-term obligations		2,721
Total liabilities	3,848,520	1,343,173
Commitments and contingencies (Note 11)
Stockholders' deficit:
Common stock, $0.001 par value, 10,000,000,000 shares authorized; 645,060,704 and 22,081,928 shares issued and outstanding as of December 31, 2016 and 2015, respectively	645,061	22,081
Additional paid-in capital	22,395,552	9,528,072
Accumulated deficit	(26,399,453)	(9,897,564)
Total stockholders' deficit	(3,358,540)	(347,411)
Total liabilities and stockholders' deficit	489,980	995,762
Series A Preferred stock
Stockholders' deficit:
Preferred stock par value
Series B Preferred stock
Stockholders' deficit:
Preferred stock par value	$ 300

Consolidated Balance Sheets (pa

Consolidated Balance Sheets (parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	645,060,704	22,081,928
Common stock, shares outstanding	645,060,704	22,081,928
Series A Preferred stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	51	0
Preferred stock, shares outstanding	51	0
Series B Preferred stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	300,000	0
Preferred stock, shares outstanding	300,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Sales
Product revenue	$ 670,176	$ 383,396
Licensing revenue	138,000
Total sales	808,176	383,396
Cost of goods sold
Product costs	481,349	221,007
Total cost of sales	481,349	221,007
Gross profit	326,827	162,389
Operating Expenses
Research and development	686,095	1,694,521
Sales and marketing	1,967,786	1,026,211
General and administrative	1,888,155	3,359,802
Total operating expenses	4,542,036	6,080,534
Loss from operations	(4,215,209)	(5,918,145)
Other expense
Interest expense, net	(2,723,187)	(447,777)
Change in fair value of derivative liability	(1,013,901)
Derivative expense	(2,464,439)
Loss on settlement of liabilities	(6,084,353)
Loss before provision for income taxes	(16,501,089)	(6,365,922)
Provision for income taxes	800	1,375
Net loss	$ (16,501,889)	$ (6,367,297)
Basic and diluted loss per common share	$ (0.19)	$ (0.35)
Weighted average shares used in computing net loss per common share basic and diluted	85,506,211	18,346,844

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity Deficit - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Convertible Preferred Stock Series A	Convertible Preferred Stock Series B
Beginning balances at Dec. 31, 2014	$ (2,210,295)	$ 10,059	$ 1,307,695	$ (3,530,267)	$ 1,620	$ 598
Beginning balances, Shares at Dec. 31, 2014		10,059,000			1,620,000	597,725
Issuance of common stock	1,593,775	$ 2,095	1,591,680
Issuance of common stock, Shares		2,094,787
Issuance of preferred stock - Series B	1,955,721		1,951,917			$ 3,804
Issuance of preferred stock - Series B, Shares						3,804,562
Issuance of preferred stock for conversion of convertible notes payable	2,070,072		2,068,190			$ 1,882
Issuance of preferred stock for conversion of convertible notes payable, Shares						1,881,884
Exchange of convertible preferred Series A stock for common stock in connection with the merger		$ 6,284				$ (6,284)
Exchange of convertible preferred Series A stock for common stock in connection with the merger, Shares		6,284,171				(6,284,171)
Exchange of convertible preferred Series B stock for common stock in connection with the merger		$ 1,620			$ (1,620)
Exchange of convertible preferred Series B stock for common stock in connection with the merger, Shares		1,620,000			(1,620,000)
Extinguishment of preferred stock warrant liability	1,943,672		1,943,672
Common stock assumed in connection with the merger		$ 1,990	(1,990)
Common stock assumed in connection with the merger, Shares		1,990,637
Proceeds from exercise of stock options	2,667	$ 33	2,634
Proceeds from exercise of stock options, Shares		33,333
Fair value of common stock warrants	147,211		147,211
Stock based compensation	517,063		517,063
Net loss	(6,367,297)			(6,367,297)
Ending balances at Dec. 31, 2015	(347,411)	$ 22,081	9,528,072	(9,897,564)
Ending balances, Shares at Dec. 31, 2015		22,081,928
Common stock issued upon conversion of convertible notes	1,836,127	$ 535,117	1,301,010
Common stock issued upon conversion of convertible notes, Shares		535,116,594
Derivative cease to exist upon conversion of notes	4,321,381		4,321,381
Issuance of common stock for services rendered	366,150	$ 10,459	355,691
Issuance of common stock for services rendered, Shares		10,459,000
Common stock issued to settle vendor liabilities	925,741	$ 46,497	879,244
Common stock issued to settle vendor liabilities, Shares		46,497,244
Common and preferred stock issued to settle payroll liabilities	5,809,090	$ 30,907	5,777,883			$ 300
Common and preferred stock issued to settle payroll liabilities, Shares		30,905,938			51	300,000
Stock based compensation	232,271		232,271
Net loss	(16,501,889)			(16,501,889)
Ending balances at Dec. 31, 2016	$ (3,358,540)	$ 645,061	$ 22,395,552	$ (26,399,453)		$ 300
Ending balances, Shares at Dec. 31, 2016		645,060,704			51	300,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (16,501,889)	$ (6,367,297)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	81,055	64,611
Impairment of assets	13,126	9,224
Common stock issued in exchange for services	366,150	1,413,002
Change in fair value of derivative liability	1,013,901
Derivative expense	2,464,439
Loss on settlement of accrued payroll	5,691,993
Loss on settlement of vendor liabilities	392,360
Stock-based compensation	232,271	517,063
Interest expense related to amortization of debt issuance costs and debt discount	1,602,635	419,798
Changes in assets and liabilities:
Accounts receivable	(17,149)	(10,702)
Inventory	296,740	(451,973)
Prepaid expenses and other assets	26,533	(108,568)
Accounts payable and accrued liabilities	3,513,462	169,533
Customer deposits	7,300	(120,404)
Current portion leases payable	(2,014)
Net cash used in operating activities	(819,087)	(4,465,713)
Cash flows from investing activities:
Purchases of property & equipment		(196,589)
Net cash used in investing activities		(196,589)
Cash flows from financing activities
Proceeds from note payable - related party	160,000	175,000
Repayment of note payable - related party	(135,000)
Proceeds from the issuance of convertible preferred stock, net of issuance costs		3,632,869
Proceeds from the issuance of convertible notes payable, net of issuance costs	521,622	250,000
Proceeds from issuance of asset based loans, net of issuance costs	300,000
Repayments on asset based loans	(133,012)
Proceeds from issuance of common stock from exercise of stock options		2,667
Net cash provided by financing activities	713,610	4,060,536
Net decrease in cash	(105,477)	(601,766)
Cash, beginning of period	143,680	745,446
Cash, end of period	38,203	143,680
Supplemental cash flow information:
Interest paid	44,200
Supplemental disclosure of non-cash investing and financing activities:
Settlement of debt with convertible note	1,836,127
Derivative cease to exist upon conversion of notes	4,321,380
Debt discount recorded on convertible debt and warrants	2,207,842
Conversion of convertible notes payable to preferred stock		2,070,072
Fair value of preferred stock warrants issued with preferred stock		1,667,148
Reclassification of warrant liability to additional paid-in capital		1,943,672
Common stock assumed in connection with merger		1,991
Conversion of convertible preferred stock to common stock		7,904
Issuance of common stock in exchange for services provided in the prior year		$ 327,100

Organization

Organization	12 Months Ended
	Dec. 31, 2016
Organization and Nature of Business [Abstract]
Organization	1. Organization MyDx, Inc. (the “Company”, “we”, “us” or “our”) (formally known as Brista Corp.) was incorporated under the laws of the State of Nevada on December 20, 2012. The Company’s wholly-owned subsidiary, CDx, Inc., was incorporated under the laws of the State of Delaware on September 16, 2013.

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2016
Organization and Nature of Business [Abstract]
Nature of Business	2. Nature of Business We are a science and technology company that has created the first battery operated, handheld, electronic analyzer for consumers. Our products leverage the latest nanotechnology to accurately measure chemicals of interest in nearly any solid, liquid, or gas sample, anywhere, anytime. Our mission is to enable people to live a healthier life by revealing the purity of certain compounds they eat, drink and inhale in real time through a device they can hold in the palm of their hand. We believe that the broad application and ease of use of our technology puts us in an ideal position to provide consumers with a practical and affordable way to Trust & Verify ® Our initial product which we introduced in the third quarter of 2015, utilizes the CannaDx sensor to allow consumers to analyze cannabis. During the third quarter of 2016 we introduced our AquaDx (water) and OrganaDx (food) sensors. Our product roadmap includes future development and commercialization of these sensors and our AeroDx (air) sensor in 2017. We will require substantial additional capital to finalize development and commercialize of our existing sensors and the AeroDx. We have a portfolio of intellectual property rights covering principles and enabling instrumentation of chemical sensing technology across solid, liquid, and gas samples, including certain patented and patent pending technologies from a third party pursuant to a joint development agreement.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2016
Going Concern [Abstract]
Going Concern	3. Going Concern The Company has elected to adopt early application of ASU No. 2014-15, “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”) The Company's consolidated financial statements have been prepared assuming it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the consolidated financial statements, the Company had an accumulated deficit at December 31, 2016, a net loss and net cash used in operating activities for the reporting period then ended. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is attempting to further implement its business plan and generate sufficient revenues; however, its cash position may not be sufficient to support its daily operations. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by early-stage companies. These risks include, but are not limited to, the uncertainty of availability of financing and the uncertainty of achieving future profitability. Management anticipates that the Company will be dependent, for the near future, on investment capital to fund operating expenses. The Company intends to position itself so that it may be able to raise funds through the capital markets. There can be no assurance that such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise capital or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. We reported negative cash flow from operations for the years ended December 31, 2016 and 2015. It is anticipated that we will continue to report negative operating cash flow in future periods, likely until one or more of our products generates sufficient revenue to cover our operating expenses. If any of the warrants are exercised, all net proceeds of the warrant exercise will be used for working capital to fund negative operating cash flow. Our cash balance of $38,203 at December 31, 2016 will not be sufficient to fund our operations for the next 12 months. Additionally, if we are unable to generate sufficient revenues to pay our expenses, we will need to raise additional funds to continue our operations. We have historically financed our operations through private equity and debt financings. The delays in our ability to ship products and generate revenues may have adversely affected our capital raising opportunities. We do not have any commitments for financing at this time, and financing may not be available to us on favorable terms, if at all. If we are unable to obtain debt or equity financing in amounts sufficient to fund our operations, if necessary, we will be forced to suspend or curtail our operations. In that event, current stockholders would likely experience a loss of most or all of their investment. Additional funding that we do obtain may be dilutive to the interests of existing stockholders. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated finance statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such management estimates include allowance for doubtful accounts, estimates of product returns, warranty expense, inventory valuation, valuation allowances of deferred taxes, stock-based compensation expenses and fair value of warrants. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable. The Company assesses these estimates on a regular basis; however, actual results could materially differ from those estimates. Concentration of Risk Related to Third-party Suppliers We depend on a limited number of third-party suppliers for the materials and components required to manufacture our products. A delay or interruption by our suppliers may harm our business, results of operations, and financial condition, and could also adversely affect our future profit margins. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must change or add new suppliers. Our dependence on our suppliers exposes us to numerous risks, including but not limited to the following: our suppliers may cease or reduce production or deliveries, raise prices, or renegotiate terms; we may be unable to locate a suitable replacement supplier on acceptable terms or on a timely basis, or at all; and delays caused by supply issues may harm our reputation, frustrate our customers, and cause them to turn to our competitors for future needs. Fair Value of Financial Instruments The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. Level 1 Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurable date. Level 2 Inputs, other than quoted prices included in Level 1, that are observable for the asset or liability through corroboration with market data at the measurement date. Level 3 Unobservable inputs that reflect management’s best estimate of what participants would use in pricing the asset or liability at the measurement date. The carrying amounts of the Company’s financial assets and liabilities, including cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short maturity of these instruments. The carrying value of the Company’s loan payable and convertible notes payable approximates fair value based upon borrowing rates currently available to the Company for loans with similar terms. Cash The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2016, and 2015, the Company held no cash equivalents. The Company’s policy is to place its cash with high credit quality financial instruments and institutions and limit the amounts invested with any one financial institution or in any type of instrument. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of December 31, 2016 and 2015, there was no allowance for doubtful accounts. Inventory Inventory is stated at the lower of cost or market value. Inventory is determined to be salable based on demand forecast within a specific time horizon, generally eighteen months or less. Inventory in excess of salable amounts and inventory which is considered obsolete based upon changes in existing technology is written off. At the point of recognition, a new lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that new cost basis. Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over the useful life as follows: Internal-use software 3 years Equipment 3 to 5 years Computer equipment 3 to 7 years Furniture and fixtures 5 to 7 years Leasehold improvements Shorter of life of asset or lease Accounting for Website Development Costs The Company capitalizes certain external and internal costs, including internal payroll costs, incurred in connection with the development of its website. These costs are capitalized beginning when the Company has entered the application development stage and cease when the project is substantially complete and is ready for its intended use. The website development costs are amortized using the straight-line method over the estimated useful life of three years. Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the condensed balance sheets and reported at the lower of the carrying amount or fair value less costs to sell, and no longer depreciated. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the condensed balance sheets. Debt Discount and Debt Issuance Costs Debt discounts and debt issuance costs incurred in connection with the issuance of debt are capitalized and amortized to interest expense based on the related debt agreements using the straight-line method. Unamortized discounts are netted against long-term debt. Derivative Liability In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Paragraph 815-15-25-1 the conversion feature and certain other features are considered embedded derivative instruments, such as a conversion reset provision, a penalty provision and redemption option, which are to be recorded at their fair value as its fair value can be separated from the convertible note and its conversion is independent of the underlying note value. The Company records the resulting discount on debt related to the conversion features at initial transaction and amortizes the discount using the effective interest rate method over the life of the debt instruments. The conversion liability is then marked to market each reporting period with the resulting gains or losses shown in the statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The Company follows ASC Section 815-40-15 (“Section 815-40-15”) to determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. Section 815-40-15 provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The adoption of Section 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible bonds issued by foreign subsidiaries with a strike price denominated in a foreign currency. The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with paragraph 810-10-05-4 and Section 815-40-25 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then that the related fair value is reclassified to equity. The Company utilizes the Black-Scholes option-pricing model to compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The Black-Scholes option-pricing model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time equal to the remaining contractual term of the instrument granted. Income Taxes Income taxes are provided in accordance with ASC No. 740, “ Accounting for Income Taxes Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company is no longer subject to tax examinations by tax authorities for years prior to 2013. Revenue Recognition The Company recognizes revenue from product sales upon shipment as long as evidence of an arrangement exists, the fee is fixed or determinable, collection of the resulting receivable is reasonably assured and title and risk of loss have passed. If those criteria are not met, then revenue will not be recognized until all of the criteria are satisfied. Product Returns For any product in its original, undamaged and unmarked condition, with its included accessories and packaging along with the original receipt (or gift receipt) within 30 days of the date the customer receives the product, the Company will exchange it or offer a refund based upon the original payment method. Customer Deposits The Company accounts for funds received from crowdfunding campaigns and pre-sales as a liability on the consolidated balance sheets as the investments made entitle the investor to apply these funds towards future shipments once the product has been developed and available for commercial use. Research and Development Costs Research and development costs are charged to expense as incurred. These costs consist primarily of salaries and direct payroll-related costs. It also includes purchased materials and services provided by independent contractors, software developed by other companies and incorporated into or used in the development of our final products. Research and development expenses for the years ended December 31, 2016 and 2015 were $686,095 and $1,694,521, respectively. Advertising Costs Advertising costs are charged to sales and marketing expenses and general and administrative expenses as incurred. Advertising expenses, which are recorded in sales and marketing and general and administrative expenses, totaled $98,219 and $40,673 for the year ended December 31, 2016 and 2015, respectively. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC Topic 718, “ Compensation – Stock Compensation” The Company accounts for share-based payments to non-employees in accordance with ASC 505-50 “ Equity Based Payments to Non-Employees Warranty The Company provides a limited warranty for its analyzers and sensors for a period of 1 year from the date of shipment that such goods will be free from material defects in material and workmanship. The Company has assessed the historical claims and, to date, warranty claims have not been significant. The Company will continue to assess the need to record a warranty accrual at the time of sale going forward. Collaborative Arrangements The Company and its collaborative partners are active participants in the collaborative arrangements and both parties are exposed to significant risks and rewards depending on the commercial success of the activity. The Company records all expenses related to collaborative arrangements as research and development expense in the consolidated statements of operations as incurred. Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which is the case for the year ended December 31, 2016 and 2015 presented in these consolidated financial statements, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. The Company had the following common stock equivalents at December 31, 2016 and 2015: December 31, December 31, Convertible notes payable 641,595,251 - Options 1,490,026 4,626,245 Warrants 7,571,395 7,571,395 Totals 650,656,672 12,197,640 Subsequent events The Company has evaluated events that occurred subsequent to December 31, 2016 and through the date the financial statements were issued. Reclassifications Certain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year presentation. These reclassifications did not affect the prior period total assets, total liabilities, stockholders' deficit, net loss or net cash used in operating activities. Recent Accounting Pronouncements In May 2014, the FASB issued a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle (issued as ASU 2014-09 by the FASB), is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, which defers the effective date of ASU 2014-09 by one year, and would allow entities the option to early adopt the new revenue standard as of the original effective date. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has evaluated the standard and does not expect the adoption will have a material effect on its consolidated financial statements and disclosures. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” ASU 2014-15 provides guidance on management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company has elected to adopt the methodologies prescribed by ASU 2014-15. The adoption of ASU 2014-15 had no material effect on its financial position or results of operations. In March 2015, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2015-03, “ Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU No. 2015-11, “ Inventory (Topic 330): Simplifying the Measurement of Inventory” In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” In April 2016, the FASB issued ASU No. 2016-09, “ Compensation – Stock Compensation” In April 2016, the FASB issued ASU No. 2016-10, “ Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net)” In May 2016, the FASB issued ASU No. 2016-12, “ Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” In October 2016, the FASB issued ASU 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory”, In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230)” Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory [Abstract]
Inventory	5. Inventory Inventory as of December 31, 2016, and 2015 is as follows: December 31, December 31, 2016 2015 Finished goods $ 3,033 $ 270,230 Raw materials 152,200 181,743 $ 155,233 $ 451,973

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2016
Property and Equipment, Net [Abstract]
Property and Equipment, net	6. Property and Equipment, net December 31, December 31, 2016 2015 Computer and test equipment $ 198,684 $ 206,499 Website development costs 39,870 39,870 Furniture and fixtures 26,948 32,845 Software 10,791 10,791 Leasehold improvements 18,288 18,288 294,581 308,293 Accumulated depreciation and amortization (155,698 ) (75,229 ) $ 138,883 $ 233,064 Depreciation expense was $80,469 and $57,944 for the year ended December 31, 2016 and 2015, respectively. For the year ended December 31, 2016, the Company recorded an impairment charge totaling $13,127 for assets that the Company no longer uses. The impairment charge is a component of general and administrative expenses on the consolidated statements of operations.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities [Abstract]
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 2016 and 2015. December 31, December 31, 2016 2015 Deferred compensation to employee $ - $ 51,210 Accrued compensation for employees 36,223 - Accrued compensation to non-employee 37,923 146,327 Accrued other 57,417 84,224 $ 131,563 $ 281,761

Debt

Debt	12 Months Ended
	Dec. 31, 2016
Debt [Abstract]
Debt	8. Debt Asset Based Loans On September 16, 2016, CDx, Inc. (the Company’s wholly owned subsidiary) entered into a Business Loan Agreement (the “Agreement”) with WebBank providing for the granting of a security interest in properties, assets and rights (the “Collateral”) as defined in the agreement. CDx, Inc. received net proceeds of $150,000. There were no loan origination or administrative fees related to the funding. The agreement has a maturity date that is 432 days after the effective date of the Agreement and requires equal weekly payments of $599 which includes a total finance fee of $34,500 over the life of the Agreement. The Agreement is personally guaranteed by an officer and majority shareholder of the Company. The outstanding balance at December 31, 2016 was $89,304. On May 31, 2016, CDx, Inc. (the Company’s wholly owned subsidiary) entered into a Promissory Note and Security Agreement (the “Note”) with Windset Capital Corporation, whereby CDx, Inc. gives, grants and assigns a continuing security interest in all of CDx, Inc.’s business equipment, accounts receivable, intellectual property, rights, licenses, claims, assets and properties of any kind whatsoever, whether now owned or hereafter acquired, real, personal, tangible, intangible or of any nature or value, wherever located, together with all proceeds including insurance proceeds as defined in the Note. There was an origination fee of $200 related to the financing. CDx, Inc. received net proceeds of $74,800 from the funding. The Note has a maturity date that is 252 business days from the date of the Note and requires payments of $360 each business day, as defined in the Note, which includes a total finance fee of $15,750 over the life of the Note. The Note is personally guaranteed by an officer and majority shareholder of the Company. The outstanding balance at December 31, 2016 was $0. On May 31, 2016, CDx, Inc. (the Company’s wholly owned subsidiary) entered into a Future Receivables Sale Agreement (the “Agreement”) with Swift Financial Corporation granting a security interest, as defined in the Agreement, in CDx, Inc.’s present and future accounts, receivables, chattel paper, deposit accounts, personal property, goods, assets and fixtures, general intangibles, instruments, equipment and inventory. There was an origination fee of $1,875 related to the financing. CDx, Inc. received net proceeds of $73,125 from the funding. The Agreement requires 48 equal weekly payments of $1,842 resulting in total repayment of $88,425 which includes a finance fee of $13,425. The total repayment amount can be reduced to $85,425 solely in the event CDx, Inc. pays this amount on or before October 3, 2016. The Agreement is personally guaranteed by an officer and majority shareholder of the Company. The outstanding balance at December 31, 2016 was $31,156. Convertible Notes December 31, December 31, 2016 2015 Convertible Notes - December 22, 2015 $ - $ 220,000 Convertible Note - December 10, 2015 - 60,000 Convertible Note -May 24, 2016 21,900 - Convertible Note -August 9, 2016 35,000 - Convertible Note – October 5, 2016 363,768 Convertible Note -November 14, 2016 35,000 - Convertible Note -November 26, 2016 63,260 Less debt discount and debt issuance costs (285,781 ) (29,152 ) Total $ 233,147 $ 250,848 Less current portion of convertible notes payable $ 233,147 $ 50,574 Long-term convertible notes payable $ - $ 200,274 The Company amortized debt discount and debt issuance costs of $1,602,635 and $419,798 for the year December 31, 2016 and 2015 respectively. On May 24, 2016, MyDx, Inc. (the “Company”) entered into a Convertible Note (the “Note”) with Vista Capital Investments, LLC (“Vista”) in the Original Principal Amount of $275,000 (including a 10% Original Issue Discount (“OID”)). The Company and Vista agreed to an initial funding under the Note of $55,000, including an OID of $5,000 (“Initial Funding”). Future advances under the Note are at the sole discretion of Vista. The Company is only required to repay the amount funded, including the prorated portion of the OID. The note bears interest at the rate of 10% and must be repaid on or before May 24, 2018. The Note may be prepaid by the Company at any time prior to the date, which is 180 days after issuance of the Note at a premium to the amount outstanding at the time of prepayment (as determined in the Note). The Note may be converted by Vista at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note). The Note also contains certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults. The foregoing is only a brief description of the Note, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements and their exhibits, which are filed as an exhibit to this Current report. The issuance of the Note was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company’s reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Note was an accredited investor. The Note might be accelerated if an event of default occurs under the terms of the Note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. The Note also contains certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rate under the Note in the event of such defaults. For the year ended December 31, 2016, the Company amortized a total of $42,352 of the debt issuance cost. As of December 31, 2016, the Note had an outstanding balance of $21,900 and a remaining unamortized debt discount of $13,148. On May 10, 2016, MyDx, Inc. (the “Company”) entered into Securities Purchase Agreement (the “SPA”) and Convertible Promissory Note in the original principal amount of $50,000 (the “Note”) with Crown Bridge Partners, LLC (“Crown”) pursuant to which Crown funded $43,000 to the Company after the deduction of a $5,000 OID and $2,000 for legal fees. The Note bears interest at the rate of 8% and must be repaid on or before May 10, 2017. The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note at a premium to the amount outstanding at the time of prepayment (as determined in the Note). The Note may be converted by Crown at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note). The SPA and Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults. The foregoing is only a brief description of the material terms of the SPA and Note, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements and their exhibits which were previously filed as an exhibit on Form 8-K. The issuance of the Note was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company’s reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Note was an accredited investor. For the year ended December 31, 2016, the Company amortized a total of $50,000, of the debt issuance cost. As of December 31, 2016, the Note had an outstanding balance of $0 and a remaining unamortized debt discount of $0. On August 9, 2016, the Company entered into Securities Purchase Agreement (the “SPA”) and Convertible Promissory Note in the original principal amount of $35,000 (the “Note”) with Crown Bridge Partners, LLC (“Crown”) pursuant to which Crown funded $30,000 to the Company after the deduction of a $3,500 original issue discount and $1,500 for legal fees. The Note bears interest at the rate of 8% and must be repaid on or before August 9, 2017. The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note at a premium to the amount outstanding at the time of prepayment (as determined in the Note). The Note may be converted by Crown at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note). The SPA and Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults. The foregoing is only a brief description of the material terms of the SPA and Note, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements and their exhibits which are filed as an exhibit to this Current Report. The issuance of the Note was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company’s reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Note was an accredited investor. For the year ended December 31, 2016, the Company amortized a total of $13,750 of the debt issuance cost. As of December 31, 2016, the Note had an outstanding balance of $35,000 and a remaining unamortized debt discount of $21,250. On May 6, 2016, the Company entered into Securities Purchase Agreement (the “SPA”) and Convertible Promissory Note in the original principal amount of $55,750 (the “Note”) with Auctus Fund, LLC (“Auctus”) pursuant to which Auctus funded $50,000 to the Company after the deduction of $5,750 of diligence and legal fees. The Note bears interest at the rate of 10% and must be repaid on or before February 6, 2017. The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note in an amount equal to 110% of the amount outstanding. The Note may be converted by Auctus at any time into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note). The SPA and Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults. The foregoing is only a brief description of the material terms of the SPA and Note, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements and their exhibits which are filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on May 10, 2016. The Company recorded the cost of the due diligence and legal fees of $5,750 as financing fees. The issuance of the Note was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company’s reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Note was an accredited investor. During the year ended December 31, 2016, the Note holder elected to convert a portion of the Note into 21,775,653 shares of the Company’s common stock. As of December 31, 2016, the Note had an outstanding balance of $0. On December 22, 2015, the Company completed a financing pursuant to a Securities Purchase Agreement with Adar Bays, LLC ("Adar Bays") providing for the issuance of two convertible promissory notes in the aggregate principal amount of $220,000, with the first note being in the amount of $110,000, and the second note being in the amount of $110,000 (the "Note" or "Notes"). The Notes contain a 10% original issue discount such that the purchase price of each Note is $100,000. The first Note was funded on December 22, 2015 and is due and payable on December 21, 2017. The second Note shall initially be paid for by the issuance of an offsetting $100,000 collateralized secured note issued by Adar Bays to the Company due and payable no later than August 21, 2016. The funding of the second Note is subject to certain conditions, and the Company may reject the closing of the second Note in its discretion. The Notes bear interest at the rate of 8% per annum and may be converted by Adar Bays at any time after the date which is nine months of the date of issuance into shares of Company common stock at a conversion price equal to 60% of the market price (as determined in the Notes) calculated at the time of conversion. The Company did not book a beneficial conversion feature in connection with the issuance of the Notes, as terms of the conversion are variable and the ultimate number of shares to be issued upon conversion could not be determined at the date the Notes were issued. As such, upon conversion of the Notes the number of shares will be determined and the Company will evaluate whether or not a beneficial conversion feature exists based on the conversion price compared to the price of the Company’s common stock at the date of issuance of the Notes. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. The Notes may be prepaid by the Company at any time prior to 180 days after the date of issuance of the Notes subject to the payment of prepayment penalties as described in the Notes. The foregoing is only a brief description of the material terms of the Securities Purchase Agreement and Notes, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements which are filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 24, 2015. The issuance of the Notes was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company's reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Notes was an accredited investor. The Company recorded the original issue discount of $10,000 as debt issuance cost on its balance sheet which is netted against the face value of the Note and is being accreted over the term of the Note. For the years ended December 31, 2016 and 2015, the Company amortized a total of $7,510 and $137, respectively, of the debt issuance cost. During the year ended December 31, 2016, the Note holder converted the Note and accrued unpaid interest into 7,142,526 share of the Company’s common stock. On June 22, 2016, MyDx, Inc. (the “Company”) and Adar Bays, LLC (“Adar Bays”) agreed to amend the Company’s 8% Convertible Promissory Note in the principal amount of $110,000 (the “Adar Bays Amendment”), issued pursuant to that certain Securities Purchase Agreement, dated December 21, 2015, entered into by and between the Company and Adar Bays, as previously disclosed in a report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 24, 2015. Pursuant to the Adar Bays Amendment, the Company agreed to redeem the note by paying 140% of the principal amount plus accrued but unpaid interests to Adar Bays, for a total redemption amount of $158,424.44, pursuant to the payment schedule set forth in the Adar Bays Amendment. In addition, the Company paid 5% of the original principal amount to Adar Bays as consideration for entering into the amendment. Adar Bays agrees not to convert the note unless the Company defaults on the payment of the redemption amount and such default is not cured within fifteen (15) business days. If the Company defaults on the redemption payment and such default is not cured as mentioned above, then the amendment shall be deemed null and void and of no further force or effect. In such event, the allocated payment made by the Company shall be applied pursuant to the payment schedule set forth in the Adar Bays Amendment. On July 29, 2016, the Company and Adar Bays agreed to terminate the standstill portion of the Adar Bays Amendment pertaining to the standstill conversion rights and Adar Bays shall be free to convert the Note without any limitations, except as required by law. All other terms and conditions of the Note and the Adar Bays Amendment shall remain in full force and effect. On August 16, 2016, the Company executed a second note with Adar Bays in the amount of $27,500 as part of the original Securities Purchase Agreement completed on December 22, 2015. The Note contains a 10% original issue discount and a documentation fee of $1,000 such that the purchase price of the Note $23,750. The note matures on August 9, 2017. The Note bears interest at the rate of 8% per annum and may be converted by Adar Bays at any time after the date which is six months of the issuance date of the original note dated December 22, 2015 into shares of Company common stock at a conversion price equal to 60% of the market price (as determined in the Notes) calculated at the time of conversion. The Company did not book a beneficial conversion feature in connection with the issuance of the Notes, as terms of the conversion are variable and the ultimate number of shares to be issued upon conversion could not be determined at the date the Notes were issued. As such, upon conversion of the Notes the number of shares will be determined and the Company will evaluate whether or not a beneficial conversion feature exists based on the conversion price compared to the price of the Company’s common stock at the date of issuance of the Notes. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. The Note may not be prepaid by the Company. The foregoing is only a brief description of the material terms of the Securities Purchase Agreement and Notes, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements which are filed as an exhibit to the Company’s Report on Form 8-K filed with the SEC on December 24, 2015. The issuance of the Note was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company's reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Notes was an accredited investor. The Company recorded the original issue discount of $2,750 as debt issuance cost on its balance sheet which is netted against the face value of the Note and is being accreted over the term of the Note. For the year ended December 31, 2016, the Company amortized a total of $2,750, of the debt issuance cost. During the year ended December 31, 2016, the Note holder elected to convert the Note and accrued and unpaid interest into 3,107,345 shares of the Company’s common stock. On September 19, 2016, the Company executed a third note with Adar Bays in the amount of $80,000 as part of the original Securities Purchase Agreement completed on December 22, 2015. The Note contains $5,000 of original issue discount and a documentation fee of $3,750 such that the purchase price of the Note $71,250. The Note matures on September 19, 2017. The Note bears interest at the rate of 8% per annum and may be converted by Adar Bays at any time after the date which is six months of the issuance date of the original note dated December 22, 2015 into shares of Company common stock at a conversion price equal to 60% of the market price (as determined in the Notes) calculated at the time of conversion. The Company did not book a beneficial conversion feature in connection with the issuance of the Notes, as terms of the conversion are variable and the ultimate number of shares to be issued upon conversion could not be determined at the date the Notes were issued. As such, upon conversion of the Notes the number of shares will be determined and the Company will evaluate whether or not a beneficial conversion feature exists based on the conversion price compared to the price of the Company’s common stock at the date of issuance of the Notes. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. The Notes may not be prepaid by the Company. The foregoing is only a brief description of the material terms of the Securities Purchase Agreement and Notes, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements which are filed as an exhibit to the Company’s Report on Form 8-K filed with the SEC on December 24, 2015. The issuance of the Note was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company's reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Notes was an accredited investor. The Company recorded the original issue discount of $2,750 as debt issuance cost on its balance sheet which is netted against the face value of the Note and is being accreted over the term of the Note. For the year ended December 31, 2016, the Company amortized a total of $3,250, of the debt issuance cost. During the year ended December 31, 2016, the Note holder elected to convert a portion of the Note into 12,045,545 shares of the Company’s common stock. As of December 31, 2016, the Note had an outstanding balance of $0. The Company amortized the entire balance of the debt issuance cost since the Note was converted in the year ended December 31, 2016. On December 22, 2015, the Company completed a financing pursuant to a Securities Purchase Agreement with Union Capital, LLC ("Union Capital") providing for the purchase of two convertible promissory notes in the aggregate principal amount of $220,000, with the first note being in the amount of $110,000, and the second note being in the amount of $110,000 (the "Note" or "Notes"). The Notes contain a 10% original issue discount such that the purchase price of each Note is $100,000. The first Note was funded on December 22, 2015 and is due and payable on December 21, 2017. The second Note shall initially be paid for by the issuance of an offsetting $100,000 collateralized secured note issued by Union Capital to the Company due and payable no later than August 21, 2016. The funding of the second Note is subject to certain conditions and the Company may reject the closing of the second Note in its discretion. The Notes bear interest at the rate of 8% per annum; are due and payable on December 21, 2017; and may be converted by Union Capital at any time after the date which is nine months of the date of issuance into shares of Company common stock at a conversion price equal to 60% of the market price (as determined in the Notes) calculated at the time of conversion. The Company did not book a beneficial conversion feature in connection with the issuance of the Notes, as terms of the conversion are variable and the ultimate number of shares to be issued upon conversion could not be determined at the date the Notes were issued. As such, upon conversion of the Notes the number of shares will be determined and the Company will evaluate whether or not a beneficial conversion feature exists based on the conversion price compared to the price of the Company’s common stock at the date of issuance of the Notes. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. The Notes may be prepaid by the Company at any time prior to 180 days after the date of issuance of the Notes subject to the payment of prepayment penalties as described in the Notes. The foregoing is only a brief description of the material terms of the Securities Purchase Agreement and Notes, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements which are filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 24, 2015. The issuance of the Notes was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company's reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Notes was an accredited investor. The Company recorded the original issue discount of $10,000 as debt issuance cost on its balance sheet which is netted against the face value of the Note and will be accreted over the term of the Note. For the year ended December 31, 2016, the Company amortized a total of $9,863, of the debt issuance cost. As of December 31, 2016 and 2015, the Note had outstanding balances of $0 and $100,137, respectively, and remaining unamortized debt discount of $0 and $9,863, respectively. During the year ended December 31, 2016, the Note holder elected to convert the Note and accrued interest of $104,500 into 7,107,376 share of the Company’s common stock. On June 22, 2016, the Company and Union Capital, LLC (“Union Capital”) agreed to amend the Company’s 8% Convertible Promissory Note in the principal amount of $110,000 (the “Union Capital Amendment”), issued pursuant to that certain Securities Purchase Agreement, dated December 21, 2015, entered into by and between the Company and Union Capital, as previously disclosed in a report on Form 8-K filed with the SEC on December 24, 2015. On July 29, 2016, the Company and Union Capital agreed to terminate the standstill portion of the Union Capital Amendment pertaining to the standstill conversion rights and Union capital shall be free to convert the Note without any limitations, except as required by law. All other terms and conditions of the Note and the Union Capital Amendment shall remain in full force and effect. Pursuant to the Union Capital Amendment, the Company agreed to redeem the note by paying 140% of the principal amount plus accrued but unpaid interests to Union Capital, for a total redemption amount of $158,363.84, pursuant to the payment schedule set forth in the Union Capital Amendment. In addition, the Company paid 5% of the original principal amount to Union Capital as consideration for entering into the amendment. Union Capital agreed not to convert the note unless the Company defaults on the payment of the redemption amount and such default is not cured within fifteen (15) business days. If the Company defaults on the redemption payment and such default is not cured as mentioned above, then the amendment shall be deemed null and void and of no further force or effect. In such event, the allocated payment made by the Company shall be applied pursuant to the payment schedule set forth in the Union Capital Amendment. During the year ended December 31, 2016, the Note holder elected to convert the Note and unpaid interest into 7,670,457 shares of the Company’s common stock. On September 19, 2016, the Company executed a sec

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2016
Derivative Liabilities [Abstract]
Derivative Liabilities	9. Derivative Liabilities The Company has identified derivative instruments arising from embedded conversion features in the Company’s Convertible Notes Payable and Accounts Payable at December 31, 2016. The Company had no financial assets measured at fair value on a recurring basis as of December 31, 2015. The following summarizes the Black-Scholes assumptions used to estimate the fair value of the derivative liability and warrant liability at the date of issuance and for the convertible notes converted during the year ended December 31, 2016. Low High Annual dividend rate 0 % 0 % Expected life 0.25 2.00 Risk-free interest rate 0.01 % 0.92 % Expected volatility 163.80 % 314.11 % Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar term on the date of the grant. Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future. Volatility: The volatility was estimated using the historical volatilities of the Company’s common stock. Remaining term: The Company’s remaining term is based on the remaining contractual maturity of the warrants. The following are the changes in the derivative liabilities during the year ended December 31, 2016. Year Ended December 31, 2016 Level 1 Level 2 Level 3 Derivative liabilities as January 1, 2016 $ - $ - $ - Addition - - 5,119,921 Conversion - - (4,321,381 ) Loss on changes in fair value - - 1,013,901 Derivative liabilities as December 31, 2016 $ - $ - $ 1,812,441 The following are the changes in the warrant liability during the year ended December 31, 2016. Year Ended December 31, 2016 Level 1 Level 2 Level 3 Fair value as January 1, 2016 $ - $ - $ - Warrants granted - - 132,867 Loss on changes in fair value - - 114,336 Fair value as December 31, 2016 $ - $ - $ 247,203

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2016
Stockholders' Deficit [Abstract]
Stockholders' Deficit	10. Stockholders’ Deficit Reverse Capitalization Pursuant to the Merger Agreement, upon consummation of the Merger, each share of CDx’s capital stock issued and outstanding immediately prior to the Merger was converted into the right to receive one (1) share of Company common stock, par value $0.001 per share. Additionally, pursuant to the Merger Agreement, upon consummation of the Merger, the Company assumed all of CDx’s options and warrants issued and outstanding immediately prior to the Merger, 6,069,960 and 7,571,395 shares of common stock, respectively. Prior to and as a condition to the closing of the Merger, each then-current Company stockholder agreed to sell certain shares of common stock held by such holder to the Company and the then-current Company stockholders retained an aggregate of 1,990,637 shares of common stock. Settlement Agreement On December 23, 2016, the Company entered into a settlement and release agreement (the “Yazbeck Settlement”) with Daniel R. Yazbeck, the Chief Executive Officer and Director of the Company (“Yazbeck”), relating to certain bona fide, outstanding, and past-due liabilities of the Company in the aggregate principal amount of approximately $321,000 for certain unpaid base salary and bonus obligations that remained deferred and/or outstanding, due and owing to Yazbeck. Under the terms of the Yazbeck Settlement, Yazbeck agreed to forgo and release any claims against the Company under that certain Employment Agreement, by and between Yazbeck and the Company, dated October 15, 2014 (the “Employment Agreement”) in exchange for (1) the issuance of fifty-one (51) shares of the Company’s Series A Preferred Stock (defined below); (2) the issuance of three hundred thousand (300,000) shares of the Company’s Series B Preferred Stock (defined below); (3) a warrant for fifteen percent (15%) of the common shares of the Company issued and outstanding as of January 3, 2017, at an exercise price of $0.001 per share, with an expiration date of January 3, 2019; and (4) the issuance of thirty million (30,000,000) shares of the Company’s restricted common stock. Preferred Stock On September 30, 2016, the Company filed a Certificate of Amendment to Articles of Incorporation with the Secretary of State of the State of Nevada to authorize for issuance ten million (10,000,000) shares of blank check preferred stock, par value $0.001 (“Blank Check Preferred Stock”) as included on Form 8-K filed with the SEC on October 4, 2016. Common Stock On February 23, 2015, the Company effected a 5-for-1 forward stock split of its issued and outstanding shares of common stock. All share and per share amounts for all periods that have been presented in the consolidated financial statements and notes thereto have been adjusted retrospectively, where applicable, to reflect the forward stock split. The Company filed a Certificate of Amendment to its Certificate of Incorporation which made the forward stock split effective and increased the authorized common shares to 375,000,000 shares with a par value $0.001 per share. In April 2015, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with CDx Merger Inc., a Nevada corporation and wholly owned subsidiary of the Company (“Merger Sub”), and CDx, Inc. (“CDx”), a Delaware corporation. Pursuant to the Merger Agreement, Merger Sub merged with and into CDx with CDx surviving the merger as the Company’s wholly owned subsidiary (the “Merger”). Pursuant to the Merger Agreement, upon consummation of the Merger, each share of CDx’s capital stock issued and outstanding immediately prior to the Merger was converted into the right to receive one (1) share of Company common stock, par value $0.001 per share (the “Common Stock”). Additionally, pursuant to the Merger Agreement, upon consummation of the Merger, the Company assumed all of CDx’s options and warrants issued and outstanding immediately prior to the Merger, 6,069,960 and 7,571,395 shares of common stock, respectively. Prior to and as a condition to the closing of the Merger, each then-current Company stockholder agreed to sell certain shares of common stock held by such holder to the Company and the then-current Company stockholders retained an aggregate of 1,990,637 shares of common stock. Therefore, following the Merger, CDx’s former stockholders now hold 19,855,295 shares of Company common stock which is approximately 91% of the Company common stock outstanding. Pursuant to the Merger Agreement, each party has made certain customary representations and warranties to the other parties thereto. The Merger was conditioned upon approval by CDx’s stockholders and certain other customary closing conditions. On April 24, 2015, in anticipation of closing the Merger, the Company changed its name to MyDx, Inc. On April 30, 2015, the Merger was consummated. Upon consummation of the Merger, the Company expanded its board of directors (the “Board”) from one to seven directors, each of whom will be directors designated by CDx. The Merger is being treated as a reverse acquisition of the Company, a public shell company, for financial accounting and reporting purposes. As such, CDx is treated as the acquirer for accounting and financial reporting purposes while the Company is treated as the acquired entity for accounting and financial reporting purposes. Further, as a result, the historical financial statements that will be reflected in the Company’s future financial statements filed with the United States Securities and Exchange Commission (“SEC”) will be those of CDx, and the Company’s assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of CDx. Each share of common stock has the right to one vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors. As a result of the Merger, the Company issued a total of 19,855,295 share of common stock to the shareholders of CDx. During the year ended December 31, 2016, the Company issued 16,654,214 shares of common stock in exchange for services at a fair value of $378,345. During the year ended December 31, 2015, the Company issued 2,094,787 shares of common stock in exchange for services at a fair value of $1,593,775. On September 30, 2016, the Company amended articles of incorporation to increase the number of authorized commons shares to 10,000,000,000 as included on Form 8-K filed with the SEC on October 4, 2016. Common Stock Warrants During the year ended December 31, 2016, the Company did not issue any warrants to purchase shares of common stock. During the year ended December 31, 2015, the Company converted warrants to purchase 4,974,567 shares of Series B preferred stock into warrants to common stock. No common stock warrants have been exercised or have expired and warrants to purchase 7,571,395 shares of common stock were outstanding as of December 31, 2016. 2015 Equity Incentive Plan In connection with the Merger on April 30, 2015, the Company adopted the MyDx, Inc. 2015 Equity Incentive Plan (the “2015 Plan”), and to date, has reserved 6,200,000 shares of common stock for issuance under the 2015 Plan. Under the 2015 Plan, employees, directors or consultants may be granted nonstatutory stock options, stock appreciation rights, restricted stock and restricted stock units to purchase shares of MyDx’s common stock. Only employees are eligible to receive incentive stock options (“ISO”) to purchase common stock. Vesting and exercise provisions are determined by the Board of Directors at the time of grant. The options generally expire ten years from the date of grant. ISOs granted to a participant who, at the time the ISO is granted, has more than 10% of the voting power between all classes of stock, will expire five years from the date of grant. Options vest at various rates ranging from immediately to three years. As of December 31, 2016, options to purchase 1,573,755 shares were available under the 2015 Plan for issuance. A summary of the Company’s stock option plan for the year ended December 31, 2016 was as follows: Shares Weighted- Outstanding as of January 1, 2015 1,937,979 $ 0.08 Granted 4,639,234 $ 0.57 Exercised (33,333 ) $ 0.08 Forfeited or cancelled (1,917,635 ) $ 0.52 Outstanding as of December 31, 2015 4,626,245 $ 0.39 Granted 125,000 $ 0.57 Exercised - $ - Forfeited or cancelled (3,261,245 ) $ 0.36 Outstanding as of December 31, 2016 1,490,000 $ 0.48 Options exercisable as of December 31, 2016 1,279,583 $ 0.22 The aggregate intrinsic value of options exercised was $0 and $15,667 for the years ended December 31, 2016 and 2015, respectively. Information regarding options outstanding and exercisable as of December 31, 2016, is as follows: Options Outstanding Options Exercisable Exercise Number Average Remaining Weighted-Average Number Weighted-Average $ 0.08 900,000 7.5 $ 0.08 900,000 $ 0.08 $ 0.55 515,000 8.2 $ 0.55 323,333 $ 0.55 $ 0.57 75,000 8.1 $ 0.57 56,250 $ 0.57 1,490,000 7.9 $ 0.27 1,279,583 $ 0.22 Total unrecognized compensation expense from employee stock options as of December 31, 2016 was $378,597 and will be recognized over a weighted average recognition period of 1.35 years. Total stock-based compensation expense, both employee and non-employee, recognized by the Company for the years ended December 31, 2016 and 2015 was $232,271 and $517,063, respectively. Stock-based compensation expense related to stock options granted to non-employees for the year ended December 31, 2016 and 2015 was $82,996 and $191,845, respectively. No tax benefits were recognized in the year ended December 31, 2016 and 2015. For the year ended December 31, 2016, the Company granted options to non-employees to purchase 125,000 shares of common stock at an exercise price of $0.57 per share as compared to 579,864 shares of common stock at an exercise price of $0.60 per share for the year ended December 31, 2015. The Company believes the fair value of the stock options is more reliably measurable than the fair value of the consulting services received. The fair value of the stock options granted is calculated at each reporting date. Additional Stock Plan Information The Company’s fair value calculations for stock-based awards under the 2015 Plan were made using the Black-Scholes option pricing model with the weighted-average assumptions set forth in the following table. Volatility is based on historical volatility rates obtained for certain public companies that operate in the same or related businesses as that of the Company since there is no market for or historical volatility data for the Company’s common stock. he risk-free interest rate is determined by using a U.S. Treasury rate for them any uses a simplified method for “plain vanilla” share options in determining the expected term of an employee share option as its equity shares are not publicly traded. The following assumptions were used in the estimated grant date fair value calculations for options granted to employees and consultants during the year ended December 31, 2016 and 2015: Years Ended December 31, 2016 2015 Dividend yield 0.0 % 0.0 % Volatility 50% - 252 52.5 % Average risk-free rate 1.04% - 2.50 % 1.65% - 1.91 % Expected term, in years 2.27 - 10.00 5.00 - 5.77 The weighted-average grant date fair value for stock options granted during the year ended December 31, 2016 and 2015 was zero and $0.27 per share.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies On April 1, 2015, the Company signed a 31-month lease for approximately 6,200 square feet of office and laboratory space at 6335 Ferris Square, Suite B, San Diego, California. The facility includes approximately 1,500 square feet of laboratory space. Commencement date of the lease is May 1, 2015. Total net rent under this lease is $247,000 and expires on November 30, 2017. The annual minimum lease payments under non-cancellable operating leases, including common area maintenance and amortization of leasehold improvements that have an initial or remaining term in excess of one year at December 31, 2016 are due as follows: 2017 81,613 Total minimum lease payments $ 81,613 Rent expense for the year ended December 31, 2016 and 2015 was $79,031 and $150,312, respectively. On April 21, 2016, the Company subleased a portion of the facility to an unrelated third party on a month-to-month basis commencing May 1, 2016. Monthly gross rent from the subtenant is $5,000 per month. Subtenant must provide the Company with ninety days prior written notice of its intent to terminate the sublease. Distribution and License Agreement and Joint Development Agreements The Company entered into a Distribution and License Agreement with a third-party for the purpose of developing a sensor array to be used in the Company’s product. The Distribution and License Agreement has an initial term of ten years, but can be terminated earlier if the project does not meet the specifications of the Company. The Company will obtain exclusive rights to sell and distribute once a successful sensor prototype is developed. In exchange for a functional prototype, the Company will pay the third-party a 7% royalty on net sales. During the year ended December 31, 2016 and 2015, the Company did not incur any development costs related to the Distribution and License Agreement. On November 1, 2013, the Company entered into a two-year Joint Development Agreement (the “Agreement”) with an unrelated third-party to develop chemical sensors and peripheral sensing equipment and software for the detection and characterization of cannabis and compounds associated with cannabis. The Agreement provides for, among other things, any arising intellectual property rights (as defined) outside of the field (as defined), and any arising intellectual property rights relating to improvements to detection materials shall belong to the Joint Venture Developer. The Agreement also provides that any arising intellectual property rights other than those covered above shall belong to the Company. To the extent that it is necessary to do so to enable the Company to use and exploit its respective arising intellectual property rights, the Joint Developer grants the Company a perpetual, irrevocable, exclusive, and royalty free license (including the right to assign the license and to grant sub-licenses) to use and exploit the Joint Developer’s arising intellectual property rights in the field. Under the terms of the Agreement, either party may cancel the Agreement as the specific tasks provided for in the Agreement have been completed or for causes specifically provided for in the Agreement. During the year ended December 31, 2015, the Company paid the Joint Developer $200,000 for development costs. On May 19, 2015, the Company entered into an Exclusive Patent Sublicense Agreement (the “License Agreement”) with Next Dimension Technologies, Inc. (“NDT”). The License Agreement grants the Company a worldwide right to the patents licensed by NDT from the California Institute of Technology. The License Agreement grants both exclusive and non-exclusive patent rights. The license granted in the License Agreement permits the Company to make, have made, use, sell and offer for sale sublicensed products in the field of use. The License Agreement continues until the expiration, revocation, invalidation or enforceability of the rights licensed. The License Agreement provides for the payment of a license fee and royalty payments by CDx to NDT. The License Agreement also contains minimum royalty payments and milestone payments by CDx to NDT. NDT has a right to terminate the License Agreement in the event of an uncured breach by CDx; the insolvency or bankruptcy of CDx; or if CDx does not meet certain productivity milestones. The License Agreement also contains representations, warranties and indemnity obligations for each of CDx and NDT. In connection with the License Agreement, on May 19, 2015, CDx and NDT also executed an Amended Amendment No. 4 (the “Amended Amendment No. 4”) to the Joint Development Agreement, dated as of November 1, 2013, between CDx and NDT, which extended the date of negotiation for the License Agreement through May 19, 2015. License and Distribution Agreement On September 1, 2016, MyDx, Inc. (the “Company” or “Licensor”) entered into a Distribution and License Agreement (the “License Agreement”) with Powerfull Holdings, Ltd, a company operating under the charter of the People’s Republic of China (“Assignor”) and China Science and Technology, a Powerfull Holdings affiliated Company (“Licensee”), (together the “Parties”). The Parties intend there to be two phases of the License Agreement: Phase One and Phase Two. During Phase One, the Licensor shall provide test samples and validation data for market validation. Subject to Phase One producing satisfactory results, and proof of concept, the Parties will commence Phase Two. For Phase One, the Licensee will pay the Licensor a minimum of Forty-Five Thousand Dollars ($45,000.00) as a Licensing and Technology Transfer Fee (the “Transfer Fee”) per application (AquaDx™, OrganaDx™, AeroDx™). These fees shall be credited towards Phase Two’s mandatory minimum payments. The Licensee shall pay the Transfer Fee within 10 business days of being provided with an invoice by the Licensor. However, should the Parties determine that the results of the activities of Phase One were not satisfactory to both parties, this Agreement shall terminate pursuant to Section 7.2(b). In connection with the agreement referenced above, the licensor and licensee are currently still operating under Phase I and the company has not yet received adequate information to enter Phase II. MyDx has not yet received and has requested market feasibility, regulatory and other studies from Licensee as contemplated under the agreement and has requested the results of their Phase I findings to be delivered to Company on or before April 21, 2017. To the extent MyDx management is unable to receive satisfactory results and confirm proof of concept, MyDx has notified Licensee it will be difficult to continue under the current agreement and the parties are permitted to terminate for cause and defectiveness in the event the products do not pass tests for quality, reliability, efficacy, and marketability or if at the completion of Phase I, the results were not satisfactory and the concept was not proven. Marketing and Advertising Advisory Services Agreement On April 5, 2016, the Company entered into a Marketing and Advertising Advisory Services Agreement (the “Agreement”) with Growth Point Advisors, Ltd. (“Growth Point”) for Growth Point to provide a comprehensive marketing, advertising and branding campaign for the Greater China Region on behalf of the Company’s MyDx AquaDx sensor. The campaign shall include, but not be limited to, the development of both the front and back-end of an e-commerce web site targeting the Chinese audience as well as introductions to potential key personnel to launch and manage the campaign. In consideration for the services described above, the Company shall pay Growth Point a monthly service fee of $30,000. Should the Company fail to pay the monthly service fee, Growth Point shall have the right to convert the monthly service fee into the Company’s common stock at a 50% discount of the lowest closing price of the Company’s common stock for the 15 trading days upon send notice of non-payment to the Company. MyDx has disputed the balance of invoice due to Growth Point. Resale Licensing Agreement On October 4, 2016, the Company executed a Resale Licensing Agreement with ANP Technologies, Inc. (“ANP”) (the “Agreement”) that outlines the terms and conditions for a One-Time, Non-Exclusive Resale License to MyDx, Inc. for the sale of ANP’s ACE-III-C pesticide and toxic heavy metal Lateral Flow Assay detection test under MyDx, Inc.’s brand. The Agreement provides for the purchase and resale of 10,000 units as part of a Phase I validation of the product’s merchantability. Litigation In the normal course of business, the Company may be subject to other legal proceedings, lawsuits and other claims. Although the ultimate aggregate amount of probable monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, the Company’s management believes that any monetary liability or financial impact to the Company from these other matters, individually and in the aggregate, would not be material to the Company’s financial condition, results of operations or cash flows. However, there can be no assurance with respect to such result, and monetary liability or financial impact to the Company from these other matters could differ materially from those projected.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Income Taxes	12. Income Taxes The components of the provision for income taxes are as follows: For the years ended December 31, 2016 2015 Current: Federal $ - $ - State 800 1,375 800 1,375 Deferred: Federal - - State - - - - Total provision for (benefit from) income taxes $ 800 $ 1,375 Deferred tax assets (liabilities) consist of the following: For the years ended 2016 2015 Deferred Tax Assets: Net operating loss carryforwards $ 4,824,505 $ 3,306,431 Research and development credits 151,303 134,724 Accruals, reserves and other 14,037 14,597 Depreciation and amortization - 35,322 Stock-based compensation 460,201 405,160 Total deferred tax asset 5,450,046 3,896,234 Valuation allowance (5,445,149 ) (3,889,501 ) Deferred tax liabilities Depreciation and amortization (4,897 ) (6,733 ) Net deferred tax assets $ - $ - Reconciliation of the statutory federal income tax to the Company's effective tax: For the year ended December 31, 2016 2015 % % Statutory federal tax rate 34.00 % 34.00 % State taxes, net of federal benefit -0.00 % -0.02 % Valuation allowance -8.89 % -32.00 % Mark to market of derivative 0 % - % Non deductible interest expense 0 % - % Other -25.11 % -2.00 % Provision for income taxes 0.00 % -0.02 % Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets of the Company will not be fully realizable for the year ended December 31, 2016 and 2015. Accordingly, management had applied a full valuation allowance against net deferred tax assets as of December 31, 2016 and 2015. The valuation allowance increased by $1,555,647 and $2,632,553 during the years ended December 31, 2016 and 2015. As of December 31, 2016, the Company had approximately $12.1 million of federal and $12.1 million of state net operating loss carryforwards available to reduce future taxable income which will begin to expire in 2033 for both federal and state purposes. As of December 31, 2016, the Company had research & development (“R&D”) credits carryforward of approximately $88,000 and $95,000 for federal and California income tax purposes, respectively. If not utilized, the federal R&D credits carryforward will begin to expire in 2034. The California credits can be carried forward indefinitely. The Company maintain liabilities for uncertain tax positions. These liabilities involve considerable judgment and estimation and are continuously monitored by management based on the best information available, including changes in tax regulations, the outcome of relevant court cases, and other information. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2016, the Company's total amount of unrecognized tax benefit was approximately $79,000 , of which none affects the effective tax rate. The Company does not expect its unrecognized benefits to change materially over the next 12 months. The Company is filing income tax returns with the United States federal government, and the state of California. The Company’s tax years 2013 through 2016 will remain open for examination by the federal and state authorities for three and four years, respectively, from the utilization of any net operating loss credits. The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Management evaluates the need to establish a valuation allowance for deferred tax assets based upon the amount of existing temporary differences, the period in which they are expected to be recovered, and expected levels of taxable income. A valuation allowance to reduce deferred tax assets is established when it is more-likely-than-not that some or all of the deferred tax assets will not be realized. Based on the Company’s net losses in prior years, management has determined that a full valuation allowance against the Company’s net deferred tax assets is appropriate. Accounting for uncertainty in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return and provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has elected to classify interest and penalties as a component of its income tax provision. With respect to the liability for unrecognized tax benefits, including related estimates of penalties and interest, the Company did not record a liability for unrecognized tax benefits as of December 31, 2016 and 201 5, respectively. The Company does not expect any changes to its unrecognized tax benefit for the next twelve months that would materially impact its consolidated financial statements.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On February 6, 2017, the principles of YCIG, Inc. (“Seller”) entered into a purchase and sale agreement where it sold the rights to the Loan Agreement to Hasper, Inc. (“Purchaser”) in exchange for the assumption of liabilities under the note and a commitment to fund additional advances to the company. Subsequently to the purchase of the note, Purchaser has funded additional advances of $20,000 to the Company. On February 7, 2017, Daniel Yazbeck funded the company an additional $25,000 in cash as an interest free bridge loan. On February 8, 2017, MyDx, Inc. entered into an option agreement (the “Option Agreement’) with the Torque Research & Development, Inc. ("TRD"). The Option Agreement provides MyDx with the exclusive right to license two patent pending inventions (the “TRD Inventions”), and requires MyDx to make annual payments to TRD as well as royalty payments on any products that are commercialized which are based on the TRD Inventions. MyDx's rights under the Option Agreement require customary measures of performance on the part of MyDx in terms of patent cost maintenance and other payments of costs associated with the TRD Inventions. With respect to the Option Agreement, MyDx rights are broad in terms of the potential access MyDx has to use the TRD Inventions in products, and services and many of the key economic terms of a future license, should MyDx exercise it’s rights under the Option Agreement, are agreed to in the Option Agreement. In addition to the Option Agreement with the TRD, on February 8, 2017, MyDx has entered into a research and development agreement (the “RD Agreement”) with TRD for the Project titled “Manufacturable, Medical Grade Smart Vape Devices and Related Medical Software Applications for Prescribers, Administrators and Patient Applications.” The RD Agreement allows MyDx to fund research based on the TRD Inventions with a three year budget of $280,371 and a deferred payment of $75,000 within ninety days of the Effective Date. The RD Agreement provides MyDx with an exclusive right to license all technology that is discovered from the monies funded to TRD through the RD Agreement (the “Derivative IP”). To the extent that MyDx exercises it’s rights under the RD Agreement, MyDx will be required to make customary annual payments to TRD, who shall be the owners of any Derivative IP, as well as royalty payments as any commercialization of such Derivative IP occurs. TRD may elect to accept payment in whole or in part in cash or the companies restricted common stock priced at the Effective Date. On February 10, 2017, the Company entered into a binding term sheet to acquire certain trademarks, software, data and customer lists from Bud Genius, Inc. in exchange for 100,000,000 restricted MyDx common stock. In good faith, the parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. The 45 days have expired and the parties continue to negotiate in good faith to consummate the transaction. On February 17, 2017 MyDx and Libre Design, LLC ("LDL") entered into a twelve (12) month Research, Branding, Advertising and Marketing Services Agreement ("Agency Agreement"). The Company agreed to pay deferred cash compensation as follows of three thousand dollars ($3,000) upon execution and one thousand five hundred dollars ($1,500) per month for a subsequent eleven (11) payments thereafter on or before the first (1st) of each month. In addition, Agency is entitled to receive sixty seven million shares of restricted common stock at a closing market price equal to .0011. On March 1 and 15th, 2017, MyDx, Inc. received a payment demand for the initial and subsequent payment of $50,000 and $25,000 per month respectively, exclusive of costs and other fees, due and owing under the BCI Advisors, LLC (“BCI”) advisory services agreement (the “Advisory Services Agreement”). The Company elected in lieu of cash to pay in unrestricted common stock, registered in form S-8. The Company made an initial payment of seventy five million shares in partial satisfaction of the amount due and owing that does not exceed the Company’s obligations under the Advisory Services Agreement to restrict BCI’s beneficial ownership to 4.99%. This summary contains only a brief description of the material terms of the Advisory Services Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such description is qualified in its entirety by reference to the Advisory Services Agreement. A copy of the Advisory Services Agreement was filed in a Current Report on Form 8-K. In March 2016, the Company sued Phoenix Fund Management, LLC (“Phoenix”) to prevent further issuances and conversion notices pursuant to, respectively, a June 2016 $250,000 Section 3(a)(10) settlement and an October 2016 $1,000,000 convertible promissory note. Between February 23, 2017 and March 8, 2017, Phoenix submitted five (5) issuance or conversion requests to the Company’s transfer agent for a total of 239,188,023 shares of the Company’s common stock. As a result of the settlement described below, none of these share were issued. On March 10, 2017, the Company entered into a Settlement Agreement with Phoenix dated March 9, 2017 (the “Phoenix Settlement”). Pursuant to the Phoenix Settlement, Phoenix has agreed it is no longer entitled to any shares pursuant to these two agreements, which are now considered paid in full. On March 15, 2017, in connection with the Phoenix Settlement, the Company filed a motion to dismiss the pending lawsuit with the Eleventh Judicial Circuit of Florida. On March 13, 2017, the Company and Bright Light Marketing, Inc. (“BLM”), in a settlement related to the Phoenix Settlement, entered into a Settlement Agreement dated March 10, 2017 (the “BLM Settlement”). In 2016, BLM notified the Company that Phoenix was a potential lender. Pursuant to the BLM Settlement, BLM will pay the Company a total of $217,500 over the next twelve (12) months. BLM is due to pay the first $100,000 within thirty (30) business days of the signing of the BLM Settlement. BLM will then pay the Company $10,000 per month on the first day of the next eleven (11) months with the final payment of $7,500 due on March 1, 2018. On March 14, 2017, the Company and Vista Capital Investments, LLC (“Vista”) entered into a Settlement Agreement dated March 14, 2017 (the “Vista Settlement”). Vista claimed, and the Company disputed, that Vista was still entitled to certain payments pursuant to convertible promissory notes the Company previously issued. On March 13, 2017, Vista submitted a conversion request of 68,437,500 shares of the Company’s common stock. Pursuant to the Vista Settlement, the Company issued 35,000,000 shares to Vista on March 14, 2017 and all convertible promissory notes issued by the Company to Vista are now considered paid in full. From November 22, 2016 through March 16, 2017, the Company has issued, in reliance upon Section 4(a)(2) of the Securities Act, 1,086,998,015 shares of common stock at a weighted average price per share of $0.001096 pursuant to conversion notices of convertible promissory notes outstanding totaling approximately $1,164,000. The shares were issued to a total of five lenders. The issuance of such convertible promissory notes was previously disclosed in the Company’s periodic reports filed with the Securities and Exchange Commission. On March 16, 2017, the Company entered into a securities purchase agreement (“SPA”) with TLG, Inc, and TRD, Inc. (“Investors”) pursuant to which the Company agreed to sell 25,000,000 restricted shares of the Company’s common stock, in an above market transaction at a purchase price of $0.004 per share for a total of $100,000. As part of the SPA, the Company granted the Investors the option, within the next 60 days, to purchase an additional 25,000,000 of restricted shares of the Company’s common stock at a purchase price of $0.006 per share for a total of $150,000. The shares of Common Stock issued pursuant to the Subscription Agreement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) and are “restricted securities" as that term is defined by Rule 144 promulgated under the Securities Act. Pursuant to the securities purchase agreement, the Investors agreed not to sell more than three hundred and seventy-five thousand shares per day (subject to adjustment for forward and reverse stock splits that occur after the date hereof) or more than seven million five hundred thousand shares per month (subject to adjustment for forward and reverse stock splits that occur after the date hereof) of the securities purchased pursuant to the SPA.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated finance statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such management estimates include allowance for doubtful accounts, estimates of product returns, warranty expense, inventory valuation, valuation allowances of deferred taxes, stock-based compensation expenses and fair value of warrants. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable. The Company assesses these estimates on a regular basis; however, actual results could materially differ from those estimates.
Concentration of Risk Related to Third-party Suppliers	Concentration of Risk Related to Third-party Suppliers We depend on a limited number of third-party suppliers for the materials and components required to manufacture our products. A delay or interruption by our suppliers may harm our business, results of operations, and financial condition, and could also adversely affect our future profit margins. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must change or add new suppliers. Our dependence on our suppliers exposes us to numerous risks, including but not limited to the following: our suppliers may cease or reduce production or deliveries, raise prices, or renegotiate terms; we may be unable to locate a suitable replacement supplier on acceptable terms or on a timely basis, or at all; and delays caused by supply issues may harm our reputation, frustrate our customers, and cause them to turn to our competitors for future needs.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. Level 1 Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurable date. Level 2 Inputs, other than quoted prices included in Level 1, that are observable for the asset or liability through corroboration with market data at the measurement date. Level 3 Unobservable inputs that reflect management’s best estimate of what participants would use in pricing the asset or liability at the measurement date. The carrying amounts of the Company’s financial assets and liabilities, including cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short maturity of these instruments. The carrying value of the Company’s loan payable and convertible notes payable approximates fair value based upon borrowing rates currently available to the Company for loans with similar terms.
Cash	Cash The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2016, and 2015, the Company held no cash equivalents. The Company’s policy is to place its cash with high credit quality financial instruments and institutions and limit the amounts invested with any one financial institution or in any type of instrument. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of December 31, 2016 and 2015, there was no allowance for doubtful accounts.
Inventory	Inventory Inventory is stated at the lower of cost or market value. Inventory is determined to be salable based on demand forecast within a specific time horizon, generally eighteen months or less. Inventory in excess of salable amounts and inventory which is considered obsolete based upon changes in existing technology is written off. At the point of recognition, a new lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that new cost basis.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over the useful life as follows: Internal-use software 3 years Equipment 3 to 5 years Computer equipment 3 to 7 years Furniture and fixtures 5 to 7 years Leasehold improvements Shorter of life of asset or lease
Accounting for Website Development Costs	Accounting for Website Development Costs The Company capitalizes certain external and internal costs, including internal payroll costs, incurred in connection with the development of its website. These costs are capitalized beginning when the Company has entered the application development stage and cease when the project is substantially complete and is ready for its intended use. The website development costs are amortized using the straight-line method over the estimated useful life of three years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the condensed balance sheets and reported at the lower of the carrying amount or fair value less costs to sell, and no longer depreciated. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the condensed balance sheets.
Debt Discount and Debt Issuance Costs	Debt Discount and Debt Issuance Costs Debt discounts and debt issuance costs incurred in connection with the issuance of debt are capitalized and amortized to interest expense based on the related debt agreements using the straight-line method. Unamortized discounts are netted against long-term debt.
Derivative Liability	Derivative Liability In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Paragraph 815-15-25-1 the conversion feature and certain other features are considered embedded derivative instruments, such as a conversion reset provision, a penalty provision and redemption option, which are to be recorded at their fair value as its fair value can be separated from the convertible note and its conversion is independent of the underlying note value. The Company records the resulting discount on debt related to the conversion features at initial transaction and amortizes the discount using the effective interest rate method over the life of the debt instruments. The conversion liability is then marked to market each reporting period with the resulting gains or losses shown in the statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The Company follows ASC Section 815-40-15 (“Section 815-40-15”) to determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. Section 815-40-15 provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The adoption of Section 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible bonds issued by foreign subsidiaries with a strike price denominated in a foreign currency. The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with paragraph 810-10-05-4 and Section 815-40-25 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then that the related fair value is reclassified to equity. The Company utilizes the Black-Scholes option-pricing model to compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The Black-Scholes option-pricing model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time equal to the remaining contractual term of the instrument granted.
Income Taxes	Income Taxes Income taxes are provided in accordance with ASC No. 740, “ Accounting for Income Taxes Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company is no longer subject to tax examinations by tax authorities for years prior to 2013.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales upon shipment as long as evidence of an arrangement exists, the fee is fixed or determinable, collection of the resulting receivable is reasonably assured and title and risk of loss have passed. If those criteria are not met, then revenue will not be recognized until all of the criteria are satisfied.
Product Returns	Product Returns For any product in its original, undamaged and unmarked condition, with its included accessories and packaging along with the original receipt (or gift receipt) within 30 days of the date the customer receives the product, the Company will exchange it or offer a refund based upon the original payment method.
Customer Deposits	Customer Deposits The Company accounts for funds received from crowdfunding campaigns and pre-sales as a liability on the consolidated balance sheets as the investments made entitle the investor to apply these funds towards future shipments once the product has been developed and available for commercial use.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred. These costs consist primarily of salaries and direct payroll-related costs. It also includes purchased materials and services provided by independent contractors, software developed by other companies and incorporated into or used in the development of our final products. Research and development expenses for the years ended December 31, 2016 and 2015 were $686,095 and $1,694,521, respectively.
Advertising Costs	Advertising Costs Advertising costs are charged to sales and marketing expenses and general and administrative expenses as incurred. Advertising expenses, which are recorded in sales and marketing and general and administrative expenses, totaled $98,219 and $40,673 for the year ended December 31, 2016 and 2015, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC Topic 718, “ Compensation – Stock Compensation” The Company accounts for share-based payments to non-employees in accordance with ASC 505-50 “ Equity Based Payments to Non-Employees
Warranty	Warranty The Company provides a limited warranty for its analyzers and sensors for a period of 1 year from the date of shipment that such goods will be free from material defects in material and workmanship. The Company has assessed the historical claims and, to date, warranty claims have not been significant. The Company will continue to assess the need to record a warranty accrual at the time of sale going forward.
Collaborative Arrangements	Collaborative Arrangements The Company and its collaborative partners are active participants in the collaborative arrangements and both parties are exposed to significant risks and rewards depending on the commercial success of the activity. The Company records all expenses related to collaborative arrangements as research and development expense in the consolidated statements of operations as incurred.
Net Loss per Share	Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which is the case for the year ended December 31, 2016 and 2015 presented in these consolidated financial statements, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. The Company had the following common stock equivalents at December 31, 2016 and 2015: December 31, December 31, Convertible notes payable 641,595,251 - Options 1,490,026 4,626,245 Warrants 7,571,395 7,571,395 Totals 650,656,672 12,197,640
Subsequent events	Subsequent events The Company has evaluated events that occurred subsequent to December 31, 2016 and through the date the financial statements were issued.
Reclassifications	Reclassifications Certain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year presentation. These reclassifications did not affect the prior period total assets, total liabilities, stockholders' deficit, net loss or net cash used in operating activities.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle (issued as ASU 2014-09 by the FASB), is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, which defers the effective date of ASU 2014-09 by one year, and would allow entities the option to early adopt the new revenue standard as of the original effective date. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has evaluated the standard and does not expect the adoption will have a material effect on its consolidated financial statements and disclosures. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” ASU 2014-15 provides guidance on management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company has elected to adopt the methodologies prescribed by ASU 2014-15. The adoption of ASU 2014-15 had no material effect on its financial position or results of operations. In March 2015, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2015-03, “ Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU No. 2015-11, “ Inventory (Topic 330): Simplifying the Measurement of Inventory” In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” In April 2016, the FASB issued ASU No. 2016-09, “ Compensation – Stock Compensation” In April 2016, the FASB issued ASU No. 2016-10, “ Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net)” In May 2016, the FASB issued ASU No. 2016-12, “ Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” In October 2016, the FASB issued ASU 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory”, In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230)” Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Summary of Significant Accounting Policies [Abstract]
Summary of depreciation and amortization are provided using the straight-line method over the useful life	Internal-use software 3 years Equipment 3 to 5 years Computer equipment 3 to 7 years Furniture and fixtures 5 to 7 years Leasehold improvements Shorter of life of asset or lease
Schedule of common stock equivalents	December 31, December 31, Convertible notes payable 641,595,251 - Options 1,490,026 4,626,245 Warrants 7,571,395 7,571,395 Totals 650,656,672 12,197,640

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory [Abstract]
Schedule of inventory	December 31, December 31, 2016 2015 Finished goods $ 3,033 $ 270,230 Raw materials 152,200 181,743 $ 155,233 $ 451,973

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Property and Equipment, Net [Abstract]
Summary of property and equipment, net	December 31, December 31, 2016 2015 Computer and test equipment $ 198,684 $ 206,499 Website development costs 39,870 39,870 Furniture and fixtures 26,948 32,845 Software 10,791 10,791 Leasehold improvements 18,288 18,288 294,581 308,293 Accumulated depreciation and amortization (155,698 ) (75,229 ) $ 138,883 $ 233,064

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities [Abstract]
Schedule of accrued liabilities	December 31, December 31, 2016 2015 Deferred compensation to employee $ - $ 51,210 Accrued compensation for employees 36,223 - Accrued compensation to non-employee 37,923 146,327 Accrued other 57,417 84,224 $ 131,563 $ 281,761

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt [Abstract]
Schedule of convertible notes	December 31, December 31, 2016 2015 Convertible Notes - December 22, 2015 $ - $ 220,000 Convertible Note - December 10, 2015 - 60,000 Convertible Note -May 24, 2016 21,900 - Convertible Note -August 9, 2016 35,000 - Convertible Note – October 5, 2016 363,768 Convertible Note -November 14, 2016 35,000 - Convertible Note -November 26, 2016 63,260 Less debt discount and debt issuance costs (285,781 ) (29,152 ) Total $ 233,147 $ 250,848 Less current portion of convertible notes payable $ 233,147 $ 50,574 Long-term convertible notes payable $ - $ 200,274
Schedule on loan agreement	Outstanding Balances as of December 31, December 31, September 29, 2015 $ - $ 25,000 October 30, 2015 - 25,000 November 4, 2015 - 25,000 November 13, 2015 - 25,000 November 20, 2015 15,000 25,000 December 1, 2015 25,000 25,000 December 2, 2015 25,000 25,000 April 6, 2016 10,000 - April 27, 2016 25,000 - July 20, 2016 25,000 - August 8, 2016 25,000 - September 19, 2016 25,000 - December 1, 2016 25,000 $ 200,000 $ 175,000

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Derivative Liabilities [Abstract]
Schedule of estimate the fair value of the derivative liability and warrant liability	Low High Annual dividend rate 0 % 0 % Expected life 0.25 2.00 Risk-free interest rate 0.01 % 0.92 % Expected volatility 163.80 % 314.11 %
Schedule of changes in the derivative liabilities	Year Ended December 31, 2016 Level 1 Level 2 Level 3 Derivative liabilities as January 1, 2016 $ - $ - $ - Addition - - 5,119,921 Conversion - - (4,321,381 ) Loss on changes in fair value - - 1,013,901 Derivative liabilities as December 31, 2016 $ - $ - $ 1,812,441
Schedule of Black-Scholes assumptions used to estimate the fair value of the derivative liability and warrant liability	Year Ended December 31, 2016 Level 1 Level 2 Level 3 Fair value as January 1, 2016 $ - $ - $ - Warrants granted - - 132,867 Loss on changes in fair value - - 114,336 Fair value as December 31, 2016 $ - $ - $ 247,203

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Deficit [Abstract]
Schedule of stock option plan	Shares Weighted- Outstanding as of January 1, 2015 1,937,979 $ 0.08 Granted 4,639,234 $ 0.57 Exercised (33,333 ) $ 0.08 Forfeited or cancelled (1,917,635 ) $ 0.52 Outstanding as of December 31, 2015 4,626,245 $ 0.39 Granted 125,000 $ 0.57 Exercised - $ - Forfeited or cancelled (3,261,245 ) $ 0.36 Outstanding as of December 31, 2016 1,490,000 $ 0.48 Options exercisable as of December 31, 2016 1,279,583 $ 0.22
Schedule of options outstanding and exercisable	Options Outstanding Options Exercisable Exercise Number Average Remaining Weighted-Average Number Weighted-Average $ 0.08 900,000 7.5 $ 0.08 900,000 $ 0.08 $ 0.55 515,000 8.2 $ 0.55 323,333 $ 0.55 $ 0.57 75,000 8.1 $ 0.57 56,250 $ 0.57 1,490,000 7.9 $ 0.27 1,279,583 $ 0.22
Summary of assumptions used in estimated grant date fair value calculations for options granted to employees and consultants	Years Ended December 31, 2016 2015 Dividend yield 0.0 % 0.0 % Volatility 50% - 252 52.5 % Average risk-free rate 1.04% - 2.50 % 1.65% - 1.91 % Expected term, in years 2.27 - 10.00 5.00 - 5.77

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Schedule of minimum lease payments under non-cancellable operating leases	2017 81,613 Total minimum lease payments $ 81,613

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Schedule of components of the provision for income taxes	For the years ended December 31, 2016 2015 Current: Federal $ - $ - State 800 1,375 800 1,375 Deferred: Federal - - State - - - - Total provision for (benefit from) income taxes $ 800 $ 1,375
Schedule of deferred tax assets (liabilities)	For the years ended 2016 2015 Deferred Tax Assets: Net operating loss carryforwards $ 4,824,505 $ 3,306,431 Research and development credits 151,303 134,724 Accruals, reserves and other 14,037 14,597 Depreciation and amortization - 35,322 Stock-based compensation 460,201 405,160 Total deferred tax asset 5,450,046 3,896,234 Valuation allowance (5,445,149 ) (3,889,501 ) Deferred tax liabilities Depreciation and amortization (4,897 ) (6,733 ) Net deferred tax assets $ - $ -
Schedule of reconciliation of the statutory federal income tax	For the year ended December 31, 2016 2015 % % Statutory federal tax rate 34.00 % 34.00 % State taxes, net of federal benefit -0.00 % -0.02 % Valuation allowance -8.89 % -32.00 % Mark to market of derivative 0 % - % Non deductible interest expense 0 % - % Other -25.11 % -2.00 % Provision for income taxes 0.00 % -0.02 %

Going Concern (Details)

Going Concern (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Going Concern (Textual)
Cash balance	$ 38,203	$ 143,680	$ 745,446

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2016
Internal-use software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Computer equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Computer equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	7 years
Furniture and fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Furniture and fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	7 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful life method description	Shorter of life of asset or lease.

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Common stock equivalents	650,656,672	12,197,640
Convertible notes payable [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock equivalents	641,595,251
Options [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock equivalents	1,490,026	4,626,245
Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock equivalents	7,571,395	7,571,395

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Summary of Significant Accounting Policies (Textual)
Cash equivalents
Allowance for doubtful accounts
Warrant policy period	1 year
Research and development expenses	$ 686,095	1,694,521
Sales and Marketing [Member]
Summary of Significant Accounting Policies (Textual)
Advertising expenses total	98,219	40,673
General and Administrative [Member]
Summary of Significant Accounting Policies (Textual)
Advertising expenses total	$ 98,219	$ 40,673

Inventory (Details)

Inventory (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory [Abstract]
Finished goods	$ 3,033	$ 270,230
Raw materials	152,200	181,743
Inventory net	$ 155,233	$ 451,973

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 294,581	$ 308,293
Accumulated depreciation and amortization	(155,698)	(75,229)
Property, plant and equipment, net	138,883	233,064
Computer and test equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	198,684	206,499
Website development costs [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	39,870	39,870
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	26,948	32,845
Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	10,791	10,791
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 18,288	$ 18,288

Property and Equipment, Net (36

Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property and Equipment, net (Textual)
Depreciation expense	$ 80,469	$ 57,944
Impairment of assets	$ 13,126	$ 9,224

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Abstract]
Deferred compensation to employee		$ 51,210
Accrued compensation for employees	36,223
Accrued compensation to non-employee	37,923	146,327
Accrued other	57,417	84,224
Accrued liabilities	$ 131,563	$ 281,761

Debt (Details)

Debt (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Short-term Debt [Line Items]
Less debt discount and debt issuance costs	$ (285,781)	$ (29,152)
Total	233,147	250,848
Less current portion of convertible notes payable	233,147	50,574
Long-term convertible notes payable		200,274
Convertible Notes - December 22, 2015 [Member]
Short-term Debt [Line Items]
Long-term convertible notes payable		220,000
Convertible Note - December 10, 2015 [Member]
Short-term Debt [Line Items]
Long-term convertible notes payable		60,000
Convertible Note -May 24, 2016 [Member]
Short-term Debt [Line Items]
Long-term convertible notes payable	21,900
Convertible Note -August 9, 2016 [Member]
Short-term Debt [Line Items]
Long-term convertible notes payable	35,000
Convertible Note - October 5, 2016 [Member]
Short-term Debt [Line Items]
Long-term convertible notes payable	363,768
Convertible Note -November 14, 2016 [Member]
Short-term Debt [Line Items]
Long-term convertible notes payable	35,000
Convertible Note -November 26, 2016 [Member]
Short-term Debt [Line Items]
Long-term convertible notes payable	$ 63,260

Debt (Details 1)

Debt (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
YCIG advance loan	$ 200,000	$ 175,000
September 29, 2015 [Member]
Related Party Transaction [Line Items]
YCIG advance loan		25,000
October 30, 2015 [Member]
Related Party Transaction [Line Items]
YCIG advance loan		25,000
November 4, 2015 [Member]
Related Party Transaction [Line Items]
YCIG advance loan		25,000
November 13, 2015 [Member]
Related Party Transaction [Line Items]
YCIG advance loan		25,000
November 20, 2015 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	15,000	25,000
December 1, 2015 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	25,000	25,000
December 2, 2015 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	25,000	25,000
April 6, 2016 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	10,000
April 27, 2016 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	25,000
July 20, 2016 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	25,000
August 8, 2016 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	25,000
September 19, 2016 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	25,000
December 1, 2016 [Member]
Related Party Transaction [Line Items]
YCIG advance loan	$ 25,000

Debt (Details Textual)

Debt (Details Textual) - USD ($)

Dec. 03, 2016

Nov. 14, 2016

Nov. 11, 2016

Oct. 19, 2016

Oct. 05, 2016

Sep. 13, 2016

Aug. 16, 2016

Aug. 09, 2016

May 10, 2016

May 06, 2016

Apr. 05, 2016

Mar. 15, 2016

Feb. 08, 2016

Dec. 10, 2015

Nov. 29, 2016

Sep. 20, 2016

Sep. 19, 2016

Sep. 16, 2016

Jul. 29, 2016

Jun. 22, 2016

May 31, 2016

May 24, 2016

Dec. 22, 2015

Dec. 31, 2016

Dec. 31, 2015

Debt (Textual)

Convertible promissory notes

$ 233,147

$ 250,848

Original issue discount amount

$ 5,000

Common stock, conversion features, description

The Company's common stock as requested by Rockwell Capital, periodically, at a 45% discount from the average lowest closing price for the 15-day trading period preceding the share request.

Convertible shares of common stock

7,670,457

Interest expense related to amortization of debt

$ 1,602,635

419,798

Cash paid

$ (250,000)

Loss on settlement of debt

(6,084,353)

Total cost of services

$ 10,000

143,900

Consulting fee

$ 1,000,000

Derivative expense

2,285,706

Securities Purchase Agreement [Member]

Debt (Textual)

Outstanding balance convertable debt

0

Convertible note principal amount

$ 35,000

$ 50,000

$ 55,750

Original issue discount amount

$ 3,500

$ 5,000

Common stock, conversion features, description

The Note into shares of Company common stock at a conversion price equal to 50% of the market price.

The Note may be converted by Crown at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price.

The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note in an amount equal to 110% of the amount outstanding. The Note may be converted by Auctus at any time into shares of Company common stock at a conversion price equal to 50% of the market price

Amortized total debt issuance cost

50,000

Funded amount

$ 30,000

$ 43,000

$ 50,000

Deduction of diligence and legal fees

$ 1,500

$ 2,000

$ 5,750

Interest rate percentage

8.00%

8.00%

10.00%

Unamortized debt issuance costs

$ 0

Convertible shares of common stock

21,775,653

Securities Purchase Agreement One [Member]

Debt (Textual)

Outstanding balance convertable debt

$ 35,000

Amortized total debt issuance cost

13,750

Unamortized debt issuance costs

21,250

Securities Purchase Agreement Two [Member]

Debt (Textual)

Outstanding balance convertable debt

0

Asset Based Loans [Member] | Business Loan Agreement [Member]

Debt (Textual)

Net proceeds received

$ 150,000

Maturity date term

432 days

Debt instrument periodic payment

$ 599

Total finance fee

$ 34,500

Outstanding balance convertable debt

89,304

Asset Based Loans [Member] | Promissory Note and Security Agreement [Member]

Debt (Textual)

Net proceeds received

$ 74,800

Maturity date term

252 days

Debt instrument periodic payment

$ 360

Total finance fee

15,750

Outstanding balance convertable debt

0

Origination fee

200

Asset Based Loans [Member] | Future Receivables Sale Agreement [Member]

Debt (Textual)

Net proceeds received

$ 73,125

Maturity date term

336 days

Debt instrument periodic payment

$ 1,842

Total finance fee

13,425

Outstanding balance convertable debt

31,156

Origination fee

1,875

Total repayment of loan

88,425

Total repayment of loan reduced

$ 85,425

Adar Bays [Member]

Debt (Textual)

Maturity date term

180 days

Convertible promissory notes

$ 27,500

80,000

$ 110,000

$ 220,000

110,000

Outstanding balance convertable debt

0

Original issue discount amount

$ 2,750

$ 2,750

$ 10,000

$ 10,000

Common stock, conversion features, description

The Note bears interest at the rate of 8% per annum and may be converted by Adar Bays at any time after the date which is six months of the date of issuance into shares of Company common stock at a conversion price equal to 60% of the market price.

The Note matures on September 19, 2017. The Note bears interest at the rate of 8% per annum and may be converted by Adar Bays at any time after the date which is six months of the issuance the original note dated December 22, 2015 into shares of Company common stock at a conversion price equal to 60% of the market price.

The Notes bear interest at the rate of 8% per annum; are due and payable on December 21, 2017; and may be converted by Union Capital at any time after the date which is nine months of the date of issuance into shares of Company common stock at a conversion price equal to 60% of the market price.

Interest rate percentage

8.00%

8.00%

8.00%

Convertible shares of common stock

7,142,526

Original issue discount rate

10.00%

10.00%

Percentage of convertible promissory note

8.00%

Percentage of redemption price

140.00%

Debt redemption amount

$ 158,424.44

Origination fee

$ 1,000

$ 3,750

Purchase price of note

$ 23,750

$ 71,250

Maturity date

Aug. 9, 2017

Sep. 19, 2017

Percentage of addition paid original principal amount

5.00%

Debt redemption description

The Company defaults on the payment of the redemption amount and such default is not cured within fifteen (15) business days.

Adar Bays [Member] | Securities Purchase Agreement [Member]

Debt (Textual)

Amortized total debt issuance cost

$ 2,750

Convertible shares of common stock

3,107,345

Union Capital, LLC [Member]

Debt (Textual)

Convertible promissory notes

$ 110,000

$ 110,000

$ 220,000

Outstanding balance convertable debt

$ 100,137

0

Original issue discount amount

$ 10,000

$ 10,000

Common stock, conversion features, description

The Notes bear interest at the rate of 8% per annum; are due and payable on September 19, 2017; and may be converted by Union Capital at any time after the date which is nine months of the date of issuance into shares of Company common stock at a conversion price equal to 60% of the market price.

The Notes bear interest at the rate of 8% per annum; are due and payable on December 21, 2017; and may be converted by Union Capital at any time after the date which is nine months of the date of issuance into shares of Company common stock at a conversion price equal to 60% of the market price.

Amortized total debt issuance cost

$ 10,000

9,863

Interest rate percentage

8.00%

8.00%

Unamortized debt issuance costs

9,863

0

Original issue discount rate

10.00%

10.00%

Percentage of convertible promissory note

8.00%

Percentage of redemption price

140.00%

Debt redemption amount

$ 158,363.84

Origination fee

$ 5,000

Purchase price of note

$ 95,000

Maturity date

Sep. 19, 2017

Percentage of addition paid original principal amount

5.00%

Debt redemption description

The Company defaults on the payment of the redemption amount and such default is not cured within fifteen (15) business days.

Union Capital, LLC [Member] | Securities Purchase Agreement [Member]

Debt (Textual)

Convertible note principal amount

$ 104,500

Convertible shares of common stock

7,107,376

Kodiak Capital Group, LLC [Member]

Debt (Textual)

Convertible promissory notes

$ 60,000

Original issue discount amount

$ 10,000

Common stock, conversion features, description

The Note may be converted by Kodiak at any time after 180 days of the date of issuance into shares of Company common stock at a conversion price equal to 50% of the market price.

The purchase price to be paid for the shares will be 70% of the market price for such shares as determined pursuant to the terms set forth in the EPA. The RRA provides that the Company will file a Registration Statement to register up to 4,000,000 shares to be sold to Kodiak pursuant to the EPA, or issued to Kodiak upon conversion of the Note, and that the Company shall use commercially reasonable efforts to file the Registration Statement before March 31, 2016. Pursuant to the terms of the EPA, the Company agreed to issue Kodiak the Note as a commitment fee.

Amortized total debt issuance cost

$ 9,426

Interest rate percentage

12.00%

Principal amount of debt

$ 50,000

Debt instrument, description

The Note must be repaid on or before February 2, 2017. The Note may be prepaid by the Company at any time without penalty. The Note may be converted by Kodiak at any time after August 2, 2016 into shares of Company common stock at a conversion price equal to 50% of the market price.

Maximum number of shares to be issued

$ 1,000,000

YCIG, Inc [Member]

Debt (Textual)

Interest rate percentage

12.00%

Maturity date

Sep. 29, 2018

EPA, RRA and Note [Member]

Debt (Textual)

Outstanding balance convertable debt

0

Original issue discount amount

10,000

Amortized total debt issuance cost

7,510

137

Unamortized debt issuance costs

0

Auctus Fund, LLC [Member]

Debt (Textual)

Total finance fee

$ 5,750

Convertible promissory notes

55,750

Convertible note principal amount

$ 55,750

Funded amount

$ 50,000

Deduction of diligence and legal fees

$ 5,750

$ 5,750

Interest rate percentage

10.00%

Convertible shares of common stock

11,819,360

Original issue discount rate

10.00%

Principal amount of debt

$ 50,000

$ 55,750

Debt instrument, description

The Note bears interest at the rate of 10% and must be repaid on or before December 15, 2016. The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note in an amount equal to 110% of the amount outstanding. The Note may be converted by Auctus at any time into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note).

The Note bears interest at the rate of 10% and must be repaid on or before December 15, 2016. The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note in an amount equal to 110% of the amount outstanding. The Note may be converted by Auctus at any time into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note).

Phoenix Fund Management, LLC [Member]

Debt (Textual)

Debt instrument, description

Phoenix Fund shares of its common stock as requested by Phoenix Fund, periodically, at a fifty percent (50%) discount from the average closing price of the Company's common stock for the 22 trading days prior to the date of issuance.

Stock exchange for retirement, shares

18,828,088

Loss on settlement of debt

$ 202,933

Adar Bays, LLC One [Member]

Debt (Textual)

Original issue discount amount

2,750

Amortized total debt issuance cost

$ 3,250

Convertible shares of common stock

12,045,545

Rockwell Capital Partners. Inc. [Member]

Debt (Textual)

Debt instrument, description

The Company shall issue and deliver to Rockwell shares of its common stock as requested by Rockwell, periodically, at a forty-five percent (45%) discount from the lowest price of the Company's common stock for the seven trading days prior to the date of issuance.

The Company shall issue and deliver to Rockwell shares of its common stock as requested by Rockwell, periodically, at a forty-five percent (45%) discount from the lowest price of the Company's common stock for the seven trading days prior to the date of issuance.

The Company shall issue and deliver to Rockwell shares of its common stock as requested by Rockwell, periodically, at a forty-five percent (45%) discount from the lowest price of the Company's common stock for the seven trading days prior to the date of issuance.

Stock exchange for retirement

$ 1,582,329

Stock exchange for retirement, shares

415,997,747

Loss on settlement of debt

$ 133,019

Crown Bridge Partners, LLC [Member]

Debt (Textual)

Total finance fee

$ 1,500

Interest rate percentage

8.00%

Principal amount of debt

$ 35,000

Debt instrument, description

The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note at a premium to the amount outstanding at the time of prepayment (as determined in the Note). The Note may be converted by Crown at any time after the nine (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price.

BCI Advisors, LLC [Member] | Advisory Services Agreement [Member]

Debt (Textual)

Debt redemption description

In addition, on the 45 and 90th day anniversary of the effectiveness of this Agreement and performance of its services, BCI shall have the right to receive a two (2) year A-1 and A-2 warrant based on a fully diluted basis, each equal to seven-and-one-half percent (7.5%) for a total of (15%) subject to adjustment of the then issued and outstanding Company common shares. The initial fee as well as A-1 and A-2 warrants have been completely earned, free of liens or encumbrances, and non-assessable and can be exercised at any time at an exercise price of $0.001 per share.

Restructuring and recapitalization

$ 50,000

Retainer fee

$ 25,000

Convertible Notes Payable [Member]

Debt (Textual)

Amortized debt discount and debt issuance costs

1,602,635

419,798

Original issue discount amount

10,000

Convertible Notes Payable [Member] | Union Capital, LLC [Member]

Debt (Textual)

Outstanding balance convertable debt

0

Convertible note principal amount

63,500

Unamortized debt issuance costs

$ 0

Convertible shares of common stock

16,487,510

Convertible Notes Payable [Member] | Kodiak Capital Group, LLC [Member]

Debt (Textual)

Convertible promissory notes

$ 50,000

Outstanding balance convertable debt

56,319

Original issue discount amount

$ 10,000

Amortized total debt issuance cost

$ 6,319

Unamortized debt issuance costs

$ 6,319

Original issue discount rate

12.00%

Principal amount of debt

$ 60,000

Debt instrument, description

The Note bears interest at the rate of 12% and must be repaid on or before February 7, 2017. The Note may be prepaid by the Company at any time without penalty prior to the date which is 180 days after the date of issuance of the Note. The Note may be converted by Kodiak at any time after 180 days of the date of issuance into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note).

Percentage of conversion price, discount

50.00%

Issuance of debt discount

$ 10,000

Convertible Notes Payable [Member] | Auctus Fund, LLC [Member]

Debt (Textual)

Outstanding balance convertable debt

$ 55,750

Convertible shares of common stock

19,211,838

Convertible Notes Payable [Member] | Vista Capital Investments, LLC [Member]

Debt (Textual)

Maturity date term

180 days

Outstanding balance convertable debt

$ 55,000

$ 21,900

Convertible note principal amount

275,000

Original issue discount amount

$ 5,000

Common stock, conversion features, description

The Note may be prepaid by the Company at any time prior to the date, which is 180 days after issuance of the Note at a premium to the amount outstanding at the time of prepayment (as determined in the Note). The Note may be converted by Vista at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50 % of the market price.

Amortized total debt issuance cost

42,352

Interest rate percentage

10.00%

Unamortized debt issuance costs

13,148

Original issue discount rate

10.00%

Convertible Notes Payable [Member] | Crown Bridge Partners, LLC [Member] | Securities Purchase Agreement [Member]

Debt (Textual)

Outstanding balance convertable debt

35,000

Original issue discount amount

$ 3,500

Amortized total debt issuance cost

4,423

Funded amount

31,500

Deduction of diligence and legal fees

$ 1,500

Interest rate percentage

8.00%

Unamortized debt issuance costs

$ 0

Principal amount of debt

$ 35,000

Debt instrument, description

The Note may be converted by Crown at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note).

Maturity date

Aug. 9, 2017

Promissory Notes One [Member] | Adar Bays [Member]

Debt (Textual)

Convertible promissory notes

$ 110,000

Principal amount of debt

100,000

Promissory Notes One [Member] | Union Capital, LLC [Member]

Debt (Textual)

Convertible promissory notes

110,000

Principal amount of debt

100,000

Promissory Notes Two [Member] | Adar Bays [Member]

Debt (Textual)

Convertible promissory notes

110,000

Principal amount of debt

100,000

Collateralized secured note issued

100,000

Promissory Notes Two [Member] | Union Capital, LLC [Member]

Debt (Textual)

Convertible promissory notes

110,000

Principal amount of debt

100,000

Collateralized secured note issued

$ 100,000

Derivative Liabilities (Details

Derivative Liabilities (Details)	12 Months Ended
	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Annual dividend rate	0.00%
Fair value of derivative liability and warrant liability [Member] | Low Level [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Annual dividend rate	0.00%
Expected life	3 months
Risk-free interest rate	0.01%
Expected volatility	163.80%
Fair value of derivative liability and warrant liability [Member] | High Level [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Annual dividend rate	0.00%
Expected life	2 years
Risk-free interest rate	0.92%
Expected volatility	314.11%

Derivative Liabilities (Detai42

Derivative Liabilities (Details 1)	12 Months Ended
	Dec. 31, 2016USD ($)
Level 1 [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative liabilities as January 1, 2016
Addition
Conversion
Loss on changes in fair value
Derivative liabilities as December 31, 2016
Level 2 [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative liabilities as January 1, 2016
Addition
Conversion
Loss on changes in fair value
Derivative liabilities as December 31, 2016
Level 3 [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative liabilities as January 1, 2016
Addition	5,119,921
Conversion	(4,321,381)
Loss on changes in fair value	1,013,901
Derivative liabilities as December 31, 2016	$ 1,812,441

Derivative Liabilities (Detai43

Derivative Liabilities (Details 2)	12 Months Ended
	Dec. 31, 2016USD ($)
Level 1 [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fair value as January 1, 2016
Warrants granted
Loss on changes in fair value
Fair value as December 31, 2016
Level 2 [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fair value as January 1, 2016
Warrants granted
Loss on changes in fair value
Fair value as December 31, 2016
Level 3 [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fair value as January 1, 2016
Warrants granted	132,867
Loss on changes in fair value	114,336
Fair value as December 31, 2016	$ 247,203

Derivative Liabilities (Detai44

Derivative Liabilities (Details Textual)	12 Months Ended
	Dec. 31, 2016
Derivative Liabilities (Textual)
Dividend yield	0.00%

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Stock option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Shares
Outstanding	4,626,245	1,937,979
Granted	125,000	4,639,234
Exercised		(33,333)
Forfeited or cancelled	(3,261,245)	(1,917,635)
Outstanding	1,490,000	4,626,245
Options exercisable	1,279,583
Weighted Average Exercise Price
Outstanding	$ 0.39	$ 0.08
Granted	0.57	0.57
Exercised		0.08
Forfeited or cancelled	0.36	0.52
Outstanding	0.48	$ 0.39
Options exercisable	$ 0.22

Stockholders' Deficit (Details

Stockholders' Deficit (Details 1) - Stock option [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,490,000
Options Outstanding, Average Remaining Contractual Life (Years)	7 years 10 months 24 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 0.27
Options Exercisable, Number Outstanding | shares	1,279,583
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 0.22
0.08 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	900,000
Options Outstanding, Average Remaining Contractual Life (Years)	7 years 6 months
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 0.08
Options Exercisable, Number Outstanding | shares	900,000
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 0.08
0.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	515,000
Options Outstanding, Average Remaining Contractual Life (Years)	8 years 2 months 12 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 0.55
Options Exercisable, Number Outstanding | shares	323,333
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 0.55
0.57 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	75,000
Options Outstanding, Average Remaining Contractual Life (Years)	8 years 1 month 6 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 0.57
Options Exercisable, Number Outstanding | shares	56,250
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 0.57

Stockholders' Deficit (Detail47

Stockholders' Deficit (Details 2)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Summary of assumptions used in the estimated grant date fair value calculations for options granted
Dividend yield	0.00%
Stock Options [Member]
Summary of assumptions used in the estimated grant date fair value calculations for options granted
Dividend yield	0.00%	0.00%
Volatility		52.50%
Maximum [Member] | Stock Options [Member]
Summary of assumptions used in the estimated grant date fair value calculations for options granted
Volatility	252.00%
Average risk-free rate	2.50%	1.91%
Expected term, in years	10 years	5 years 9 months 7 days
Minimum [Member] | Stock Options [Member]
Summary of assumptions used in the estimated grant date fair value calculations for options granted
Volatility	50.00%
Average risk-free rate	1.04%	1.65%
Expected term, in years	2 years 3 months 7 days	5 years

Stockholders' Deficit (Detail48

Stockholders' Deficit (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Dec. 23, 2016	Apr. 30, 2015	Feb. 23, 2015	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
Stockholders' Deficit (Textual)
Common stock, par value				$ 0.001	$ 0.001
Common stock, shares authorized				10,000,000,000	10,000,000,000
Shares of common stock in exchange for services fair value				$ 1,522,690
Series B Preferred Stock [Member]
Stockholders' Deficit (Textual)
Preferred stock, par value				$ 0.001	$ 0.001
Warrants to purchase shares of common stock					4,974,567
2015 Equity Incentive Plan [Member]
Stockholders' Deficit (Textual)
Reserved shares of common stock		6,200,000
Percentage of voting interests acquired		10.00%
Options expiration description		The options generally expire ten years from the date of grant. ISOs granted to a participant who, at the time the ISO is granted, has more than 10% of the voting power between all classes of stock, will expire five years from the date of grant.
Unrecognized compensation expense				$ 378,597
Weighted average recognition period				1 year 4 months 6 days
Purchase shares of common stock granted options to non-employees				125,000	579,864
Exercise price				$ 0.57	$ 0.60
Stock options granted to non-employees				82,996	191,845
Weighted-average grant date fair value for stock options granted				$ 0	$ 0.27
Option to puchase of common shares				1,573,755
Employee and non-employee stock-based compensation expense				$ 232,271	$ 517,063
Aggregate intrinsic value of options exercised value				$ 0	$ 15,667
Common stock [Member]
Stockholders' Deficit (Textual)
Common stock, par value			$ 0.001
Common stock, shares authorized			375,000,000			10,000,000,000
Forward stock split shares of common stock, Description			5-for-1
Stock issued during period, Shares					2,094,787
Shares of common stock in exchange for services				16,654,214	2,094,787
Shares of common stock in exchange for services fair value				$ 378,345	$ 1,593,775
Blank Check Preferred Stock [Member]
Stockholders' Deficit (Textual)
Preferred stock, par value						$ 0.001
Authorize for issuance of shares of blank check preferred stock						10,000,000
Common Stock Warrants [Member]
Stockholders' Deficit (Textual)
Warrants to purchase shares of common stock				7,571,395
Settlement Agreement [Member]
Stockholders' Deficit (Textual)
Stock description of transaction	Under the terms of the Yazbeck Settlement, Yazbeck agreed to forgo and release any claims against the Company under that certain Employment Agreement, by and between Yazbeck and the Company, dated October 15, 2014 (the "Employment Agreement") in exchange for (1) the issuance of fifty-one (51) shares of the Company's Series A Preferred Stock (defined below); (2) the issuance of three hundred thousand (300,000) shares of the Company's Series B Preferred Stock (defined below); (3) a warrant for fifteen percent (15%) of the common shares of the Company issued and outstanding as of January 3, 2017, at an exercise price of $0.001 per share, with an expiration date of January 3, 2019; and (4) the issuance of thirty million (30,000,000) shares of the Company's restricted common stock.
Aggregate principal amount	$ 321,000
CDx's [Member]
Stockholders' Deficit (Textual)
Warrants converted into the right to receive share of company common stock		1		1
Common stock, par value		$ 0.001		$ 0.001
Warrants issued shares of common stock		6,069,960		6,069,960
Warrants outstanding shares of common stock		7,571,395		7,571,395
Retained shares of common stock		1,990,637		1,990,637
Issuance of common stock option		6,191,000
CDx's [Member] | Common stock [Member]
Stockholders' Deficit (Textual)
Stock issued during period, Shares		19,855,295		19,855,295
Percentage of beneficial ownership		91.00%

Commitments and Contingencies49

Commitments and Contingencies (Details)	Dec. 31, 2016USD ($)
Minimum lease payments under non-cancellable operating leases
2,017	$ 81,613
Total minimum lease payments	$ 81,613

Commitments and Contingencies50

Commitments and Contingencies (Details Textual)	Oct. 04, 2016shares	Sep. 01, 2016USD ($)	Apr. 05, 2016USD ($)	Apr. 21, 2016USD ($)	Apr. 01, 2015USD ($)ft²	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Commitments and contingencies (Textual)
Rent expense						$ 79,031	$ 150,312
Rent from subtenant				$ 5,000
Distribution and license agreement term						10 years
Royalty percentage						7.00%
Resale Licensing Agreement [Member]
Commitments and contingencies (Textual)
Purchase and resale of units | shares	10,000
License and Distribution Agreement [Member] | Phase One [Member]
Commitments and contingencies (Textual)
Licensing and Technology transfer fee		$ 45,000
Joint Developer [Member]
Commitments and contingencies (Textual)
Development costs							$ 200,000
Marketing and Advertising Advisory Services Agreement [Member]
Commitments and contingencies (Textual)
Monthly service fee			$ 30,000
Percentage of conversion units of discount			50.00%
Common stock trading days			15 days
San Diego, California[Member]
Commitments and contingencies (Textual)
Total area | ft²					1,500
Commencement date of lease					May 1, 2015
Rent expense					$ 247,000
Term of lease					31 months
Area of land, description					Company signed a 31-month lease for approximately 6,200 square feet of office and laboratory space at 6335 Ferris Square, Suite B, San Diego, California.
Lease expires					Nov. 30, 2017

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal
State	800	1,375
Total current income taxes	800	1,375
Deferred:
Federal
State
Total deferred income taxes
Total provision for (benefit from) income taxes	$ 800	$ 1,375

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred Tax Assets:
Net operating loss carryforwards	$ 4,824,505	$ 3,306,431
Research and development credits	151,303	134,724
Accruals, reserves and other	14,037	14,597
Depreciation and amortization		35,322
Stock-based compensation	460,201	405,160
Total deferred tax asset	5,450,046	3,896,234
Valuation allowance	(5,445,149)	(3,889,501)
Deferred tax liabilities
Depreciation and amortization	(4,897)	(6,733)
Net deferred tax assets

Income Taxes (Details 2)

Income Taxes (Details 2)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Statutory federal tax rate	34.00%	34.00%
State taxes, net of federal benefit	0.00%	(0.02%)
Valuation allowance	(8.89%)	(32.00%)
Mark to market of derivative	0.00%
Non deductible interest expense	0.00%
Other	(25.11%)	(2.00%)
Provision for income taxes	0.00%	(0.02%)

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes (Textual)
Valuation allowance increased amount	$ 1,555,647	$ 2,632,553
Unrecognized tax benefits	79,000
Federal [Member]
Income Taxes (Textual)
Net operating loss carryforwards	$ 12,100,000
Operating loss carryforwards, Expiration date	Dec. 31, 2033
Credit carryforward, Amount	$ 88,000
Credit carryforward, Expiration date	Dec. 31, 2034
State [Member]
Income Taxes (Textual)
Net operating loss carryforwards	$ 12,100,000
California [Member]
Income Taxes (Textual)
Credit carryforward, Amount	$ 95,000

Subsequent Events (Details)

Subsequent Events (Details)

Mar. 15, 2017USD ($)

Mar. 14, 2017shares

Mar. 13, 2017USD ($)shares

Mar. 01, 2017USD ($)

Feb. 10, 2017shares

Feb. 08, 2017USD ($)

Feb. 06, 2017USD ($)

Mar. 08, 2017shares

Feb. 17, 2017

Oct. 31, 2016USD ($)

Jun. 30, 2016USD ($)

Mar. 16, 2017USD ($)Lenders$ / sharesshares

Feb. 07, 2017USD ($)

Aug. 09, 2016USD ($)

May 10, 2016USD ($)

May 06, 2016USD ($)

Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Debt instrument annual principal payment

$ 35,000

$ 50,000

$ 55,750

Convertible promissory note [Member]

Subsequent Event [Line Items]

Conversion of amount

$ 1,000,000

$ 250,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Debt instrument periodic payment

$ 25,000

$ 50,000

Percentage of beneficial ownership

4.99%

Subsequent Event [Member] | Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Sale of restricted shares | shares

25,000,000

Purchase price | $ / shares

$ 0.004

sale of stock amount

$ 100,000

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Investor [Member]

Subsequent Event [Line Items]

Sale of restricted shares | shares

25,000,000

Purchase price | $ / shares

$ 0.006

sale of stock amount

$ 150,000

Subsequent Event [Member] | Hasper, Inc. [Member]

Subsequent Event [Line Items]

Additional advance of fund

$ 20,000

Subsequent Event [Member] | TRD [Member]

Subsequent Event [Line Items]

Three year budget amount

$ 280,371

TRD Invention term

3 years

Description of debt instruments

The RD Agreement allows MyDx to fund research based on the TRD Inventions with a three year budget of $280,371 and a deferred payment of $75,000 within ninety days of the Effective Date.

Debt instrument periodic payment

$ 75,000

Subsequent Event [Member] | Bud Genius, Inc. [Member]

Subsequent Event [Line Items]

Description of debt instruments

The parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. The 45 days have expired and the parties continue to negotiate in good faith to consummate the transaction.

Restricted share of MyDx stock | shares

100,000,000

Subsequent Event [Member] | MyDx [Member] | Libre Design, LLC [Member]

Subsequent Event [Line Items]

Deferred compensation arrangements overall description

The Company agreed to pay deferred cash compensation as follows of three thousand dollars ($3,000) upon execution and one thousand five hundred dollars ($1,500) per month for a subsequent eleven (11) payments thereafter on or before the first (1st) of each month. In addition, Agency is entitled to receive sixty seven million shares of restricted common stock at a closing market price equal to .0011.

Subsequent Event [Member] | Bridge Loan [Member]

Subsequent Event [Line Items]

Additional cash for interest free bridge loan

$ 25,000

Subsequent Event [Member] | Convertible promissory note [Member]

Subsequent Event [Line Items]

Conversion of amount

$ 1,164,000

Converted into common stock shares | shares

239,188,023

1,086,998,015

Weighted average price per share | $ / shares

$ 0.001096

Number of lenders | Lenders

5

Subsequent Event [Member] | Convertible promissory note [Member] | Vista [Member]

Subsequent Event [Line Items]

Converted into common stock shares | shares

35,000,000

Subsequent Event [Member] | Settlement Agreement [Member] | BLM [Member]

Subsequent Event [Line Items]

Description of debt instruments

The Company and Bright Light Marketing, Inc. ("BLM"), in a settlement related to the Phoenix Settlement, entered into a Settlement Agreement dated March 10, 2017 (the "BLM Settlement"). In 2016, BLM notified the Company that Phoenix was a potential lender. Pursuant to the BLM Settlement, BLM will pay the Company a total of $217,500 over the next twelve (12) months. BLM is due to pay the first $100,000 within thirty (30) business days of the signing of the BLM Settlement. BLM will then pay the Company $10,000 per month on the first day of the next eleven (11) months with the final payment of $7,500 due on March 1, 2018.

Debt instrument periodic payment

$ 10,000

Debt instrument annual principal payment

217,500

Debt instrument first payment

100,000

Debt instrument final paymment

$ 75,000

Debt Instrument due date

Mar. 1, 2018

Settlement agreement date

Mar. 10, 2017

Subsequent Event [Member] | Settlement Agreement [Member] | Vista [Member]

Subsequent Event [Line Items]

Converted into common stock shares | shares

68,437,500

Settlement agreement date

Mar. 14, 2017